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Dietary fat provides essential nutrients, contributes to energy balance, and 
regulates blood lipid concentrations. These functions are important to health, but can also 
become dysregulated and contribute to diseases such as obesity, diabetes, and 
cardiovascular disease. The small intestine absorbs dietary fat through an efficient multi 
step process of digestion, uptake, metabolism, and secretion or storage. When dietary fat 
is taken up by the absorptive cells of the small intestine, enterocytes, it can be secreted 
into circulation where it contributes to blood lipid levels or temporarily stored in 
cytoplasmic lipid droplets (CLDs). The objective of this dissertation is to investigate the 
presence and metabolism of CLDs in the intestine. 
Dietary fat absorption by the small intestine is a multi-step process that regulates 
the uptake and delivery of essential nutrients and energy. One step of this process is the 
temporary storage of dietary fat in cytoplasmic lipid droplets (CLDs). The storage and 
mobilization of dietary fat is thought to be regulated by proteins that associate with the 
CLD; however, mechanistic details of this process are currently unknown. In this study 
we analyzed the proteome of CLDs isolated from enterocytes harvested from the small 




proteins associated with the CLD fraction, of which 37 are associated with known lipid 
related metabolic pathways. We confirmed the localization of several of these proteins on 
or around the CLD through confocal and electron microscopy, including perilipin 3, 
apolipoprotein A-IV, and acyl-CoA synthetase long-chain family member 5. The 
identification of the enterocyte CLD proteome provides new insight into potential 
regulators of CLD metabolism and the process of dietary fat absorption.   
 We also investigated the effect of diet induced obesity on CLD morphology and 
associated proteins. It is currently unclear what effect diet induced obesity (DIO) has on 
the balance between dietary fat storage and secretion. Specifically, there is limited 
knowledge of how DIO affects the level and diversity of proteins that associate with 
CLDs and regulate CLD dynamics. In the current study, we characterize CLDs from lean 
and DIO mice through histological and proteomic analyses. We demonstrate that DIO 
mice have larger intestinal CLDs compared to lean mice in response to dietary fat. 
Additionally we identified 375 proteins associated with CLDs in lean and DIO mice. We 
identify a subgroup of lipid related proteins which are either increased or unique to the 
DIO CLD proteome. These proteins are involved in steroid synthesis pathways, TAG 
synthesis, and lipolysis. This analysis expands upon our knowledge of the effect of DIO 
obesity on the process of dietary fat absorption in the small intestine. 
 Lastly, we investigated the role of one of the newly identified CLD associated 
proteins on dietary fat absorption. Little is known of the role of Acsl5 in the metabolism 
of dietary fat in enterocytes. To understand the role of Acsl5 in dietary fat absorption, we 
challenged WT and Acsl5-deficient mice with acute and chronic dietary fat challenges. 




significantly reduced TAG storage and secretion by enterocytes compared to WT mice.  
Interestingly, Acsl5-deficient consumed more food, but did not gain more weight 
compared to WT mice during two weeks of HFD feeding. Furthermore, we found that 
Acsl5 localizes to the nucleus after an acute dietary fat challenge. Together this data 
suggests that although Acsl5 is not essential for quantitative dietary fat absorption, it 
plays a role in intestinal metabolism of dietary fat. 
The results presented in this dissertation provide new knowledge of regulators of 
CLD metabolism. The long term objectives of these studies are to identify mechanistic 
details of the process of intestinal dietary fat absorption. Understanding the process of 
dietary fat absorption will provide new treatments for the prevention of diseases 
associated with dyslipidemia. 
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Portions of this section have been previously published in: 
T. D'Aquila, Y.H. Hung, A. Carreiro, K.K. Buhman, Recent discoveries on absorption of 
dietary fat: Presence, synthesis, and metabolism of cytoplasmic lipid droplets within 
enterocytes, Biochimica et biophysica acta, 1861 (2016) 730-747. 
 
CHAPTER 1. INTRODUCTION 
1.1 Dietary fat, health, and disease 
1.1.1 Dietary fat structure and composition 
Dietary fat represents a diverse group of chemical compounds with different 
structures, functions, health benefits, and risk for disease. Dietary fat is a broad 
classification for lipid compounds which are consumed[1]. Dietary fat can be found from 
both animal and plant sources and is a significant source of energy. In the western diet, 
dietary fat accounts for approximately 35% of calories consumed. The predominant form 
of dietary fat consumed is the form of long chain triacylglycerol (TAG), which is 
composed of 3 fatty acids esterified to a glycerol backbone. Dietary fat also contains 
smaller amounts of cholesteryl esters (CE) and phospholipids (PL). Fatty acids are 
present within TAG, CE, or PL and consist of a chain of carbons of various chain lengths 
and degree of saturation. Fatty acid species include saturated fatty acids, 
monounsaturated fatty acids, polyunsaturated fatty acids (including omega 6 and 3 fatty 




1.1.2 Dietary fat, fat soluble vitamins, and essential fatty acids 
Dietary fat plays a critical role in health by promoting the absorption of essential 
nutrients of fat soluble vitamins and essential fatty acids[2]. Vitamins A (in the form of 
retinol esters), vitamin D, vitamin E, and vitamin K, are fat soluble vitamins whose 
absorption is dependent on the presence of fat in the diet. These vitamins enter the 
circulation as components of chylomicrons [2] [3]. Malabsorption of these vitamins may 
lead to deficiency and ultimately xerophthalmia, rickets, neuromuscular disorders, 
hemorrhaging. Essential fatty acids are also absorbed by the intestine and secreted into 
circulation [4]. Essential fatty acid deficiency, while rare, can result in neurological and 
cognitive development problems. The small intestine plays an essential role in the 
absorption of fat soluble vitamins, essential fatty acids, and promotion of health. 
 
1.1.3 Dietary fat and risk for disease 
Dietary fat plays a critical role in the etiology of cardiovascular disease [5]. The 
association of diet composition and risk for coronary heart disease has been extensively 
studied for the last 50 years. Despite intense investigation, the link between dietary fat 
and coronary heart disease is a contested subject. In 1977, public health officials 
recommended to limit intake of dietary fat to less than 30% of daily calories in an effort 
to reduce the risk for coronary artery disease[6]. To assess the impact of these 
recommendations, The Women's Health Initiative Randomized Controlled Dietary 
Modification Trial, tested low fat (20% kcal from fat)/high carbohydrate intervention diet 




reducing dietary fat on risk for coronary artery disease and cardiovascular disease [7]. 
This lack luster result shifted the attention from total dietary fat to dietary fatty acid 
composition. 
Diets high in saturated fat have been implicated in an increased risk for coronary 
artery disease. Dietary intervention trials which reduced saturated fat or replaced 
saturated fat with other fatty acid types reduced cardiomorbidity and cardiovascular 
events, but no had effect on cardiovascular mortality [8]. Based on numerous intervention 
trials and meta-analyses, the National Heart Foundation of Australia recommended 
reducing saturated and trans-fat intake and increasing omega 3, omega 6, and 
monounsaturated fatty acid intake, to reduce the risk of cardiovascular disease [9].  
The United States has recently changed dietary guidelines to help Americans eat a 
healthier diet. The 2015 dietary guidelines suggest limiting the intake of calories from 
saturated fat to less than 10% of total calories. Additionally, the dietary guideline 
advisory committee suggests replacing saturated fat with polyunsaturated fat to reduce 
the risk for coronary artery disease [10]. More specifically, current guidelines suggest 
reducing trans fats and saturated fats to 1 and 7% respectively and replacing these fats 
with polyunsaturated and monounsaturated fatty acids [11]. Understanding the molecular 
mechanisms by which the small intestine absorbs dietary fat is critical for the prevention 





1.2 Intestinal metabolism of dietary fat 
1.2.1 Digestion and uptake of dietary fat 
The small intestine absorbs dietary fat through an efficient multi step process of 
digestion, uptake, metabolism, and secretion or storage. Dietary fat absorption is an 
extremely efficient process (greater than 98%) even when large amounts of dietary fat are 
consumed [12]. Disruption of the process of dietary fat digestion, uptake, metabolism, 
and secretion results in fat malabsorption as indicated by steatorrhea or presence of fat in 
the feces.  
Dietary fats are digested and emulsified in the lumen of the small intestine and 
ultimately taken up by enterocytes through the apical brush border membrane. Crude 
emulsion of dietary fat enters the small intestine from the stomach and is combined with 
bile acids from the gall bladder/liver and pancreatic juices. In the lumen of the small 
intestine, dietary fat is emulsified into mixed micelles with bile acids and phospholipids 
and undergo hydrolysis by pancreatic lipase [13]. The digestion of dietary TAG results in 
the production of free fatty acids (FFA) and sn-2 monoacylglycerol (MAG) [14] that are 





1.2.2 Fatty acid uptake and metabolism 
FFA and MAG are taken up by enterocytes however the mechanisms through 
which this occurs is not completely clear. MAG passively diffuses across the plasma 
membrane of enterocytes [15]. FFA on the other hand may be taken up by the enterocytes 
by passive diffusion or by protein mediated uptake [16]. FFA may diffuse passively 
across the plasma membrane via a flip flop mechanism. Since long chain fatty acid 
(LCFA) uptake by diffusion is a saturable process [17], a protein dependent mechanism 
has been proposed to promote cellular uptake of FFA. FFA may be facilitated across the 
plasma membrane by CD36, by enterocytes in the proximal section of the small intestine. 
Isolated enterocytes from the proximal section of CD36 deficient mice have decreased 
rate (50%) of fatty acid uptake [18]. In particular, CD36 has a high affinity and promotes 
absorption of very long chain fatty acids [19]. FFA may be facilitated across the plasma 
membrane by fatty acid transport protein 4 (FATP4). FATP4 is present on the apical side 
of the enterocyte and when overexpressed, increases the uptake of LCFA [20]. 
Interestingly, both CD36 and FATP4 deficient mice have no fat malabsorption. It has 
been suggested that CD36 and FATP4 may play important however non-essential roles in 
regulating dietary fat absorption. Although the mechanism through which fatty acids are 
taken up is unclear, the intestine is capable of responding to high lipid load as 
demonstrated by low fecal lipid content in healthy humans. 
FFA may be metabolically trapped in enterocytes via fatty acid binding proteins 
and directed toward specific metabolic fates. The upper region of the small intestine 




intestinal FABP. Both FABP1 and FABP2 are highly expressed in the small intestine and 
have a high affinity for LCFA [21]. It is hypothesized that FABP1 and FABP2 bind to 
FFA in enterocytes and limit the toxic effects of FFA [22]. FABP1 has high binding 
affinity for fatty acids but also other lipid species such as lysophospholipids, MAG, fatty 
acyl-coA, and prostaglandins [23]. FABP1 deficient mice have increased deposition of 
lumenally derived MAG into PL, MAG, and diacylglycerol (DAG) and with a decreased 
deposition in TAG. This data indicates FABP1 directs dietary MAG toward TAG 
synthesis. FABP1 deficient mice have a decrease deposition of lumenally derived fatty 
acids into mucosal oxidation indicating FABP1 directs fatty acids toward oxidation [24]. 
FABP2 on the other hand has a high binding affinity for fatty acids but has not been 
shown to have non fatty acid ligands. FABP2 deficient mice have increased deposition of 
lumenally derived fatty acids into PL and decreased into TAG indicating FABP2 directs 
fatty acids into TAG synthesis and away from PL synthesis. Interestingly, both FABP1 
and FABP2 deficient mice do not have fat malabsorption as indicated by steatorrhea on 
chow or high fat diets. While the roles of these two proteins in the intestine is not 
completely clear, FABP1 and FABP2 may play a role in fatty acids transport and 
targeting of fatty acids towards different metabolic fates [25]. 
FFA may be metabolically trapped in enterocytes by conversion to fatty acyl-CoA 
and directed toward specific metabolic fates. The thioesterification of LCFA to a long 
chain fatty acyl-CoA is catalyzed by long chain fatty acyl-CoA synthetases (ACSLs) and 
is an obligatory step in the cellular lipid metabolism. There are at least 25 different acyl-
CoA synthetases with different tissue distribution patterns [26]. The primary ACSLs 




fatty acid uptake via vectorial acylation [27]. Vectorial acylation has not been 
investigated in the small intestine, however FATP4 inhibition in isolated enterocytes by 
antisense oligonucleotides reduces the uptake of LCFA [20]. The role of Acsl5 in fatty 
acid uptake in enterocytes is unknown. In addition to driving fatty acid uptake, ACSLs 
have been proposed to partition fatty acids toward specific metabolic fates [28]. ACSL 
partitioning of fatty acids has been characterized in other cell types but has not been fully 
investigated in enterocytes. Acsl5 directs fatty acyl-coA toward TAG synthesis in a cell 
model of hepatocytes [29]. The role of Acsl5 in intestinal dietary fat absorption has not 
been thoroughly investigated. Initial report of Acsl5 deletion in mice shows a 60% 
decrease in jejunal ACSL activity but no difference in TAG secretion in response to an 
acute dietary fat challenge [30]. Intestinal deletion of FATP4 does not affect TAG 
secretion or fecal lipid content in response to an acute dietary fat challenge, however 
iFATP4 deficient mice have increased fecal lipid TAG content when placed on a Western 
diet when compared to wild type mice [31]. The investigators report no changes in 
expression of other FATPs in iFATP4 deficient mice, however Acsl5 expression was not 
measured and potentially compensates for loss of iFATP4. These results indicate highly 
expressed ACSLs in the intestine are dispensable for dietary fat absorption. 
 
1.2.3 Fatty acid re-esterification 
Fatty acids are re-esterified generating a TAG molecule through the glycerol-3-
phosphate (G3P) and acyl-coA: monoacylglycerol acyltransferase (MGAT) pathways. 




3-phosphate acyltransferase (GPAT) enzymes and yields lysophosphatidic acid [32]. In 
the small intestine, two isoforms of GPAT are expressed: GPAT3 (high expression, 
jejunum) and GPAT4 (moderate expression) [32-34]. Gpat3-deficient mice have 
decreased TAG secretion and increased TAG storage in enterocytes following a dietary 
fat challenge [33]. The lysophophatidic acid formed during this first reaction is then 
acylated by acylglycerolphosphate acyltransferase (AGPAT) enzymes, also known as 
lysophosphatidic acid acyltransferases, to form phosphatidic acid. In the small intestine, 
AGPAT2, AGPAT4 or AGPAT8 may contribute to the formation of phosphatidic acid. 
Lipin enzymes, or phosphatidic acid phosphatases (PAPs), then remove the phosphate 
group to form DAG. Lipin-3 mRNA is present in the small intestine of mice and humans 
[35]. The presence of players in the G3P pathway and results found in Gpat3-deficient 
mice highlight that this pathway may play a more important role in intestinal TAG 
metabolism than previously recognized. 
Alternatively, free fatty acids may be re-esterified by the MGAT pathway. MGAT 
activity accounts for 70-80% of TAG generated for secretion [36]. Multiple MGAT 
enzymes have been identified and are differentially expressed in tissues and species. The 
first step of the MGAT pathway for TAG synthesis is the acylation of MAG by fatty 
acyl-CoA to produce DAG, which is catalyzed by MGAT activity (reviewed in [37]). 
MGAT activity is highest in the proximal small intestine and progressively decreases in 
distal regions [38]. Three MGAT isoforms have been identified, but only MGAT2 and 
MGAT3 are present in the small intestine [39]. MGAT2 is abundant in the intestine of 
both mice and humans, with both mRNA and protein levels reflecting MGAT activity 




humans, but not mice, and is highest in the ileum [40]. The role of MGAT2 in dietary fat 
absorption has been investigated in mouse models. Mgat2 protein and mRNA levels 
increase in response to a high fat diet, suggesting this enzyme contributes to the increase 
in MGAT activity that occurs during dietary fat absorption [38]. Two different Mogat2-
deficient mouse models were generated to understand the function of Mgat2 in intestinal 
TAG synthesis and dietary fat absorption [41, 42]. Although these mice still synthesize 
TAG in enterocytes and secrete CM-sized lipoproteins, they exhibit a reduced 
postprandial triglyceridemic response and a decreased TAG secretion rate in response to 
an oral fat load compared to wild-type mice [41, 42]. In addition, they remain efficient at 
absorbing dietary fat when fed a high fat diet. These results suggest that although other 
enzymes must be present to catalyze this activity, the fate of TAG synthesized in 
enterocytes may be different in Mogat2-deficient mice than wild-type mice. In fact, while 
less TAG is secreted in the Mogat2-deficient mouse models, more TAG is found in CLDs 
of jejunal enterocytes in Mogat2-deficient mice fed a high fat diet than in wild-type mice 
[41]. Similar effects have been observed in intestine-specific Mogat2-deficient mice [43] 
and in mice treated with an MGAT2 inhibitor [44]. In addition, restoring Mogat2 
expression specifically in the intestine of Mogat2-deficient mice normalized the TAG 
absorption rate [45]. Together these results suggest that MGAT2 is not critical for 
absorption, but important for balancing intestinal TAG storage and secretion. Whether 
DAG is generated via G3P or MGAT pathway, the final step in TAG synthesis is 




1.2.4 Triacylglycerol synthesis 
Acyl Co-A: diacylglycerol acyltransferase (DGAT) catalyzes the final step in 
TAG synthesis. Two proteins with DGAT activity have been identified and investigated 
in intestinal lipid metabolism. DGAT enzymes catalyze the acylation of DAG, resulting 
in the formation of TAG [37, 39]. This reaction is the final, committed step of TAG 
synthesis, and is the point at which the MGAT and G3P pathways converge. Evidence of 
DGAT activity on both the luminal (latent activity) and cytosolic (overt activity) sides of 
the ER in rat liver microsomes suggests that distinct pools of TAG destined for storage 
and secretion may be present in lipoprotein-producing cells [46]. Total DGAT activity is 
highest in the proximal intestine and decreases distally along the length of the intestine 
[47]. The two known DGAT enzymes, DGAT1 and DGAT2, are both integral ER 
membrane proteins and are both present in the small intestine. DGAT2 has also been 
shown to localize to CLDs and associate with mitochondria in other cell types [48, 49]. 
Although both of these enzymes catalyze the same reaction, they are members of two 
different gene families, and differ from one another in terms of structure, expression 
pattern, and biochemical properties. This suggests that DGAT1 and DGAT2 may play 
unique roles in synthesizing TAG for storage versus secretion in enterocytes. 
 
1.2.5 Chylomicron synthesis and secretion 
TAG can be packaged onto chylomicrons (CM) for secretion from enterocytes. 
CMs are the major TAG rich lipoprotein produced by enterocytes in response to a meal 




the ER and are then secreted via pre-CM transport vesicles (PCTVs) through the Golgi 
and secretory pathway on the basolateral side of the enterocyte to lymph [51]. First, 
TAGs and CEs are synthesized by enzymes that localize to the ER membrane. These 
neutral lipids are packaged onto apolipoprotein (APO) B48 with the help of microsomal 
triglyceride transfer protein (MTP or Mttp) [52]. APOB48 serves as a lipid acceptor and 
structural protein of CMs. MTP serves as a lipid transfer protein and chaperone for 
maintaining APOB48 structure. The neutral lipids, TAGs and CE, are surrounded by a PL 
monolayer containing free cholesterol and proteins. This initial structure is referred to as 
the primordial CM [53]. The second step in the synthesis of pre-CMs is the expansion of 
the CM core by TAG [54]. The mechanisms underlying the addition of TAG is unclear 
but it is known that MTP is required, and apoB-free ER lumenal lipid droplets (LLDs) are 
the most likely source of TAG for core expansion [55, 56] . One possible mechanism for 
this expansion is the fusion of LLDs with primordial CMs. Alternatively, it has been 
suggested that hydrolysis and re-esterification of LLDs may provide lipids for the second 
step of core expansion during CM assembly [55]. 
Pre-CMs exit the ER and are transported to the Golgi for further processing. 
These particles are transported within PCTVs containing coat protein complex II (COPII). 
COPII is made up of five core proteins: secretion associated, Ras related 1B (Sar1B) 
GTPase, Sec23, Sec24, Sec13, and Sec31 [56, 57]. The budding of PCTVs from the 
surface of the ER is mediated by liver fatty acid binding protein [58, 59] and protein 
kinase C isoform zeta [60]. PCTVs are larger than protein transport vesicles (250 nm 
versus 55–70 nm, respectively) and also contain the unique vesicle-associated membrane 




pre-CMs are further modified by addition of APOAI [63] and glycosylation of APOB48 
[64]. Mature CMs are then destined for secretion where they are released from the 
basolateral side of the enterocyte by exocytosis to the lamina propria as imaged by 
transmission electron microscopy [65, 66]. The contractile movement of lacteals mediates 
the process of CM drainage to mesenteric lymphatic vessels [67]. CMs are then 
transported via the thoracic duct that empties into circulation at the left subclavian vein. 
In addition to the nonexchangeable APOB48, several exchangeable apolipoproteins can 
be found on the surface of CMs, including APOAI, APOAII, APOAIV, APOC and 
APOE [68]. 
The importance of the role in dietary fat absorption in health is highlighted by 
human congenital disorders where proteins chylomicron synthesis and secretion are 
defective or deficient [69]. Deficiencies in ApoB, Mttp, and Sar1b result in 
hypobetalipoproteinemia, abetalipoproteinemia, and chylomicron retention disease 
respectively. These diseases are characterized by fat malabsorption presenting as 
steatorrhea, low blood lipid (TAG and CHOL) levels, deficiencies in fat soluble vitamins 
and essential fatty acids and ultimately failure to thrive. 
 
1.2.6 Cytoplasmic lipid droplets and triacylglycerol storage 
Alternatively to secretion in CM, dietary TAG can be stored in CLDs within 
enterocytes. The partitioning of TAG into CM synthesis has been well characterized and 
less is known regarding the synthesis and catabolism of CLDs in enterocytes. The 




blood. The molecular mechanisms of CLD metabolism in enterocytes are relatively 
unknown. Identification of mediators of intestinal CLD metabolism has the potential to 
significantly impact the dietary fat absorption and ultimately health and disease. 
 
1.3 Cytoplasmic lipid droplet metabolism 
1.3.1 General knowledge of CLD metabolism 
1.3.1.1 Physiological conditions promoting CLDs 
Cytoplasmic lipid droplets are the main site of lipid storage in eukaryotic cells. 
CLDs are efficient stores of excess energy and are generated when nutrients are present 
in excess. Almost every cell type is capable of generating CLDs, however the size, 
number, composition, and metabolism of CLDs varies based on cell type and 
physiological conditions. While CLD characteristics differ, there are some common 
features. This section will highlight general characteristics of CLD biology and 
metabolism and the following sections will focus on CLDs specifically in the small 
intestine. 
 
1.3.1.2 CLD composition 
CLDs are composed of a neutral lipid core, surrounded by a phospholipid 
monolayer and a coat of associated proteins. Additionally, CLDs may be physically 




and function of CLDs. The composition of CLD components vary based on cell type and 
physiological condition. For example, CLDs in adipocytes are long term energy stores 
while CLDs in hepatocytes and enterocytes are more transient stores for excess fatty 
acids. Additionally, the presence, composition, and metabolism of CLDs may affect cell, 
tissue, and organism, physiology and function. 
 
1.3.1.2.1 Neutral and phospholipid composition 
CLDs are composed of a neutral lipid core with a phospholipid monolayer coat. 
The neutral lipid core is predominantly TAG and sterol esters however additional 
hydrophobic compounds have been detected in isolated CLDs albeit at much lower levels. 
These lipid species include retinyl esters, wax esters, and ether lipids [70, 71]. The 
surface of the CLD is comprised of phospholipids, mainly phsophstidylcholine, 
phosphatidylethanolamine, and phosphatidynlinositol [70]. This amphipathic interface 
allows for the interaction with proteins and other organelles [72]. 
 
1.3.1.2.2 General CLD associated proteins 
Various proteins associate with the CLD and regulate CLD metabolism. Perilipin 
(Plin) was the first protein identified associated with the CLD in 1991 [73]. Since the 
initial discovery of Plin, other members of the perilipin family have been identified 
across species with similar sequence and ability to bind to CLDs [74]. The members of 
the perilipin family include, Plin1 (Perilipin), Plin2 (Adipocyte differentiation related 




47), Plin4 (Adipocyte protein S3-12, or S3-12), and Plin5 (Lipid droplet-associated 
protein PAT-1 or OxPAT). It is still unclear what role the different Plin family members 
play in regulating CLD metabolism. While members of the Plin family are often 
characterized as regulators of CLD catabolism, new research suggest a potential role in 
glucose homeostasis [75, 76]. A large number of studies have been performed to identify 
additional proteins associated with CLDs from a variety of cell types under various 
physiological conditions. Fueled by technological advances and association of CLDs with 
various metabolic disorders, the field of CLD biology has advance dramatically in the last 
10 years.  
A current gap in the field revolves around the targeting proteins to CLDs. Proteins 
may embed directly into the CLD by a hydrophobic hairpin motif or associate with the 
surface of the CLD by amphipathic helices or hydrophobic domains [77]. Additionally 
the ability of a protein to bind to CLDs may change during CLD growth and metabolism 
[78].  During lipolysis, CLD surface area decreases resulting in “protein crowding” and 
ultimately the removal of proteins which are more loosely bound to the CLD. The 
removal of proteins during CLD shrinkage has the potential to alter CLD composition 
and metabolism. Understanding which proteins associate with CLDs during CLD 




1.3.1.3 CLD connection with organelles 
CLDs are highly connected organelles that physically interact with ER, other 
CLDs, mitochondria, and lysosomes [79]. CLDs are thought to emerge from the ER and 
may maintain a physical connection or close contact with the ER [80]. The bridge 
between ER and CLDs has been suggested to facilitate the transport of proteins and lipids 
between the two organelles [49] [81]. This is also a proposed mechanism of CLD growth. 
Additionally, CLDs are connected to other CLDs through CIDE proteins. Both CIDEC 
and CIDEA localize to CLD contact sites [82, 83]. CLDs are also connected or closely 
associated with mitochondria. Fatty acids mobilized from CLD stores can channel to 
mitochondria for oxidation [84], although the proteins which mediate the interaction 
between the two organelles remain unknown. CLDs are connected to autophagosomes. 
Electron microscopy images demonstrate that autophagosomes surround the CLD during 
starvation conditions in hepatocytes to mobilize stored TAG [85]. The process of lipid 
mobilization through the process of lipophagy will be described later. Recognition of 
CLDs as highly connected organelles is transforming the concept of CLDs from mere 
lipid storage sites to central players in whole cell metabolism. 
 
1.3.1.4 Roles of CLDs 
CLDs store excess energy and help protect cells from free fatty acid induced 
cytotoxicity. Tissues specialized in energy storage, such as adipose tissue, can store 
incredible amounts of energy in the form of TAG and stored in CLDs. A non-obese 




about 30 marathons [72]. Additionally, CLDs protect cells against toxic effects of free 
fatty acids. Excess non esterified free fatty acids or cholesterol can trigger cell membrane 
damage and trigger inflammatory responses. When esterified to TAG or CE and stored in 
CLDs, excess fatty acids are buffered against the cellular environment and serve as a 
source of lipid for cellular processes. 
CLDs serve as a source of fatty acids for cell function. Fatty acids mobilized from 
CLD stores can be used to provide energy for the cell through oxidation. Fatty acids 
mobilized from CLDs can be used to generate complex lipids. Fatty acids can be used for 
synthesis of PL, CE, or TAG. CLDs may also serve as a source of fatty acids or other 
lipid species functioning as signaling molecules. Adipose triglyceride lipase (ATGL), a 
cytosolic lipase that localizes to the CLD, catalyzes the hydrolysis of a FFA from stored 
TAG in the lipid droplet. The resulting FFA potentially acts as a ligand for peroxisome 
proliferator- activated receptor alpha (PPARa). Liver specific knockdown of ATGL 
decreases the expression of PPARa target genes and the effect is reversed when PPARa 
agonists are administered [86].  
More recently, CLDs have been hypothesized to serve as protein storage sites. 
The most well characterized example of CLDs serving as protein depot is during 
embryogenesis in Drosphilia. Histones localize to CLDs until needed for cell replication 
[87]. Alternatively, CLDs may serve as a site for targeting proteins for degradation. In 
particular ApoB has been shown to localize to CLDs and aggregate when proteasomal 
degradation is inhibited [88]. Lastly, proteins may transiently localize to CLDs to be 




1.3.1.5 CLD synthesis 
CLDs are generated and expand through multiple mechanisms. There are several 
proposed models of CLD biogenesis, including ER budding, bicellar excision, and vesicle 
formation (reviewed in [90]). The model with the most current support is ER budding. In 
the ER budding model, the accumulation of neutral lipids within the ER membrane 
bilayer eventually leads to the budding of a CLD, with the cytosolic ER membrane leaflet 
forming its PL monolayer. This budding process may be driven solely by lipid 
accumulation, or mediated by proteins that bind to the ER membrane. A model of CLD 
synthesis with less support, the bicellar model, involves neutral lipid accumulation in the 
ER membrane followed by excision of this lipid along with both surrounding membrane 
leaflets. The issue with this model is that it would result in a transient hole in the ER 
membrane. Another model of CLD synthesis with less support is the formation of CLDs 
within bilayer vesicles. This mechanism would be mediated by vesicle formation 
machinery of the secretory pathway, and the lipid accumulation could occur either within 
the ER or after the vesicle buds. The precise mechanism of CLD synthesis in the small 
intestine has not been directly investigated. Once CLDs are formed, they are able to 
continue to accumulate TAG and increase in size. One mechanism of CLD growth is 
through TAG synthesis locally at the CLD surface [49, 90]. PL synthesis is important for 
CLD monolayer expansion in this growth mechanism. A second mechanism for CLD 
growth is through fusion of CLDs [90, 91]. Although there is not much known about 





TAG synthesis is known to occur at the ER membrane, but more recently this 
process has been observed at the CLD surface and shown to contribute locally to the 
growth of CLDs (reviewed in [90]). For this to occur, TAG synthesis machinery needs to 
localize to the CLD surface. One isoform of each of the enzymes involved in the G3P 
pathway of TAG synthesis (GPAT4, AGPAT3, PAP, and DGAT2) has been shown to 
localize to CLDs in either Drosophila S2 cells, 3T3-L1 adipocytes, or COS7 cells [48] 
[49] and [92]. In addition, specific isoforms of enzymes that activate FAs to form acyl-
CoAs for incorporation into TAG (ACSL1, ACSL3, and ACSL4) have been identified on 
CLDs in several cell types (reviewed in [93]). In enterocytes, TAG synthesis enzymes 
that have been identified on CLDs are ACSL3, ACSL4, ACSL5, GPAT3 and MGAT2 in 
mice and humans (reviewed in [33] and [94]). Of these, ACSL3 [95], ACSL5 [96], and 
GPAT3 [33] have been validated by confocal or electron microscopy to be present on 
CLDs in enterocytes. 
During CLD growth, additional PLs are required for expansion of the PL 
monolayer surrounding CLDs to prevent their coalescence [97]. Phosphatidylcholine (PC) 
is the most abundant PL in these structures, and plays an important role in CLD growth 
[97, 98]. Three pathways mediate PC synthesis and are present in most cell types. These 
pathways include the de novo, or Kennedy pathway, the phosphatidylethanolamine 





1.3.1.6 CLD catabolism 
Lipolysis mediates the biochemical hydrolysis of neutral lipids and CLD 
catabolism. The biochemical reaction of lipolysis is catalyzed by enzymes that hydrolyze 
ester bonds of lipids including TAGs, CEs, and PLs. TAGs are hydrolyzed to glycerol 
and FAs, CEs are hydrolyzed to free cholesterol and FAs and PLs are hydrolyzed to 
lysophospholipids and FAs. In a cell, lipolysis often refers to the breakdown of CLDs; 
however, lipolysis can take place wherever lipids containing ester bonds are present. 
Through lipolysis, the neutral lipids in the core of CLDs are able to be mobilized to a 
variety of metabolic fates.  
There are two identified pathways that mediate lipolysis of CLDs in cells. 
Cytoplasmic TAG lipolysis is the most well-known pathway and has been defined 
primarily by studies in adipocytes (reviewed in [99]). Lipophagy is a newly-identified 
pathway and refers to the selective degradation of CLDs through autophagy (reviewed in 
[100]). The enzymes and co-activator involved in cytoplasmic TAG lipolysis and 
lipophagy are present and associate with CLDs in multiple cell types. 
 
1.3.1.6.1 Adipose Triglyceride Lipase 
ATGL catalyzes the first step of cytoplasmic lipolysis by hydrolyzing an ester 
bond in TAG to generate DAG and FA [101]. TAG storage in CLDs inversely correlates 
with ATGL activity in enterocytes. In enterocytes of C. elegans, reducing ATGL activity 




ATGL activity by overexpression decreases TAG storage in CLDs [102]. In addition, 
whole body Atgl-deficient mice have a severe defect in lipolysis and abnormal 
accumulation of TAG in CLDs in many tissues (including enterocytes), and they develop 
obesity [103]. 
 
1.3.1.6.2 Comparative Gene Identification- 58 
CGI-58 is a cofactor that regulates ATGL activity and is present in intestine of 
humans, mice and C. elegans. CGI-58 binds to ATGL and is required for efficient ATGL 
activity; however, it has no measurable hydrolase activity [104]. Mutations in CGI-58 in 
humans cause Chanarin–Dorfman Syndrome [105]. Chanarin–Dorfman Syndrome is a 
rare genetic disease resulting in ichthyosis and abnormal lipid accumulation in multiple 
tissues including the intestine [106]. CGI-58 also plays an important role in mouse 
physiology, including intestinal lipid metabolism. Whole body Cgi-58-deficient mice die 
shortly after birth due to a severe skin barrier defect [107]. 
 
1.3.1.6.3 Hormone Sensitive Lipase 
HSL has broad substrate specificity; but is thought to primarily catalyze the 
second step of TAG hydrolysis, the hydrolysis of an ester bond in DAG to generate MAG 
and FA. HSL also possesses hydrolytic activity towards TAGs, MAGs, CEs and retinoid 




mice accumulate DAGs in adipose and non-adipose tissues but do not develop obesity 
[109, 110]. The link between HSL deficiency and human disease is not clear; however, a 
recent clinical study identified a frameshift mutation in the LIPE gene (encodes HSL) 
that reduces adipose tissue lipolysis in both basal and stimulated states [111].  
 
1.3.1.6.4 Monoacylglycerol Lipase 
MGL catalyzes the final step of cytoplasmic lipolysis by hydrolyzing MAG to 
glycerol and FA. MGL localizes not only to CLDs, but also cell membranes and the 
cytoplasm  [112]. Beyond hydrolyzing dietary MAG species, MGL also hydrolyzes the 
endogenous cannabinoid 2-arachidonylglycerol and is known to regulate cannabinoid 
signaling in the central nervous system (reviewed in [113]). Therefore, effects of altered 
MGL expression may be due to either TAG hydrolysis or cannabinoid signaling, and are 
challenging to differentiate. Mouse models deficient in MGL have a decreased rate of 
lipolysis and accumulation of MAG [114]. 
 
1.3.1.6.5 Putative methods of CLD catabolism 
Several lines of evidence suggest the presence of additional lipases particularly in 
non-adipose tissue (Reviewed in [115]). In the liver, ATGL accounts for less than 50% of 
TAG hydrolysis [116] and ATGL deficient mice develop hepatosteatosis [103]. Residual 
TAG activity in ATGL deficient mice and normal VLDL production suggest the presence 
of additional TAG hydrolases in the liver. While putative lipases have been briefly 




1.3.1.6.5.1 Arylacetamide deacetylase 
In addition to classical lipases and mediators of autophagy, several putative 
lipases have recently been identified. Arylacetamide deacetylase (Aadac) is an enzyme 
with mRNA expression in hepatocytes, intestinal mucosa, pancreas, and adrenal glands 
[117]. Aadac has sequence homology with hormone sensitive lipase. In the intestine Aada 
mRNA levels increased with fenofibrate administration. In the liver Aadac is 
characterized as a putative microsomal triglyceride lipase [118]. HuH7.5 cells, a human  
hepatoma cell line, expressing a short hairpin RNA targeting Aadac has impaired TAG 
lipolysis and VLDL secretion. This data indicates that Aadac may play a role in TAG 
lipolysis in non--adipose cell types. 
 
1.3.1.6.5.2 Carboxylesterase 
Members of the carboxylesterase family are potential lipases. Carboxylesterase 3 
(Ces1d, or triglyceride hydrolyze) has triglyceride hydrolase activity [119]. Liver specific 
deletion of Ces3 results in reduced plasma TAG without hepatosteatosis [120].  Other 
members of the carboxylesterase family have not been investigated for their role in TAG 
lipolysis. 
 1.3.1.6.5.3 Autophagy 
Autophagy is the catabolic process that breaks down cellular components 
sequestered within double-membrane organelles called autophagosomes by transporting 




autophagy which are delivered by autophagosomes to lysosomes, where lysosomal acid 
lipase (LAL) hydrolyzes ester bonds in lipids. This process is referred to as lipophagy 
(reviewed in [100]). LAL is expressed ubiquitously and is responsible for hydrolyzing 
ester bonds in TAGs and CEs within the lysosome, generating free cholesterol, glycerol 
and FAs. Mutations in LAL in humans result in two diseases: Wolman disease (complete 
loss of LAL) and CE storage disease (CESD; partial loss of LAL) [121, 122]. Patients 
with Wolman disease usually have failure to thrive during infancy due to severe 
gastrointestinal issues including vomiting, diarrhea and malabsorption. Massive storage 
of TAGs and CEs are observed in the liver and small intestine of these patients[123].  
Whole-body Lal-deficient mice have similar features of Wolman disease. These mice can 
survive into adulthood, but have a shorter lifespan than wild-type mice [124]. 
 
1.3.2 CLD protein in enterocytes 
1.3.2.1 Physiological conditions promoting CLDs in enterocytes 
CLDs are present in the small intestine when chylomicron synthesis is inhibited 
and in response to a high fat meal. CLDs are present in the intestine when there are 
deficiencies in proteins involved in chylomicron synthesis including ApoB, Mttp, and 
Sar1b result in hypobetalipoproteinemia, abetalipoproteinemia, and chylomicron 
retention disease. These diseases are characterized by accumulation of TAG in 
enterocytes which results in steatorrhea due to enterocyte turnover. These diseases are 
also characterized by low blood lipid (TAG and CHOL) levels, deficiencies in fat soluble 




present in the intestine when chylomicron synthesis and release is inhibited by chemical 
inhibitors. A commonly used non-ionic hydrophobic surfactant known as Pluronic L-81 
reversibly inhibit the transport of intestinal chylomicrons [125]. Pluronic L-81 treated 
mice accumulate TAG in enterocytes in response to a meal, however it is not clear if 
TAG accumulates in CLD or in other cellular organelles such as the ER or the Golgi. 
Lastly, CLDs are transiently present in the intestine after a high fat meal. TAG levels in 
enterocytes increase and decrease over time [126]. 
 
1.3.2.2 CLD composition 
1.3.2.2.1 Neutral and phospholipid composition 
CLDs in enterocytes contain neutral lipids, phospholipids, and highly 
hydrophobic lipids. Isolated CLDs contain primarily TAG but also cholesterol ester, 
diacylglycerol ether, and phospholipid, when Caco-2 cells were exposed to mixed 
micelles containing 2 mM sodiumtaurocholate, 0.6 mM oleic acid, 0.2 mM 
lysophosphatidylcholine, 0.05 mM cholesterol and 0.2 mM 1-O-octadecyl-rac-glycerol 
[127].  In a separate experiment CLDs were isolated from the duodenum after a 
cholesterol (2%) and sunflower oil challenge. The lipid content of these isolated CLDs 
were analyzed by lipidomics and found to contain triglyceride, cholesterol ester, free 
cholesterol, phosphatidylcholine, sphingomyelin, ceramides, free fatty acids and mono 
and di-acylglycerols. Not surprisingly, the lipid species found in isolated CLDs 





Members of the perilipin family associate with CLDs in enterocytes. The first 
proteins identified associated with CLDs in enterocytes were members of the PLIN 
family, perilipin 2 (Plin2, also adipocyte related protein (ADRP) or adipophilin)) and 
Plin3 (also Tip47) [129]. These proteins were investigated because the PLIN family of 
proteins is well established to associate with CLDs and regulate lipid storage and 
hydrolysis in many cell types [130]. Plin2 and Plin3 are the only members of the family 
identified in intestine and are differentially expressed and localize to CLDs in enterocytes 
based on specific dietary conditions. Plin3, an exchangeable CLD associated protein, 
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and is absent from CLDs during fasting, as well as in chronic high-fat fed mice in the fed 
state, as determined by immunofluorescence microscopy [129].  
The role of Plin2 in dietary fat absorption was further investigated in a Plin2-
deficient mouse model [131]. Plin2-deficient mice have increased fecal TAG content and 
decreased CLDs in jejunum and ileum when fed either low-fat or high-fat diets compared 
to wild-type mice. Although the effects of Plin2-deficiency on CM synthesis and 
secretion were not investigated, these results indicate that Plin2 plays a role in dietary fat 




1.3.2.3 CLDs may serve multiple roles in the enterocyte 
CLDs may protect enterocytes from free fatty acid toxicity[132].CLDs may help 
regulate the rate and amount of dietary fat absorption after a meal by serving as a sink 
and store of dietary TAG. After a meal, dietary fat can go toward chylomicron synthesis 
or toward storage in CLDs. Additionally, CLDs may regulate the length of the post 
prandial period by controlling the mobilization of stored TAG for chylomicron synthesis.  
CLDs may regulate the rate of steroid synthesis. Several proteins associated with steroid 





    -hydroxysteroid dehydrogenase 2 
(DHB2), and Oestradiol 17- -dehydrogenase 11 (HSD17B11). While the small intestine 
is not typically classified as a steroidogenic organ, the presence of steroid hormone 
metabolism proteins associated with the CLD suggests local production or metabolism of 
steroids.  
The FAs or lipids released from enterocyte CLDs have the potential to serve as 
signaling molecules that regulate intestinal and/or systemic physiology. These FAs or 
lipids may serve as ligands for transcription factors, or substrates for synthesizing 
specialized, bioactive lipids that regulate diverse cellular functions. In the small intestine, 
FAs and lipids act as ligands for trans	 	     !"  ##$"
(see details in Section 5.3). In addition, arachidonic acid is the major FA precursor for 
synthesizing eicosanoids (such as prostaglandins, leukotrienes, and other related 
molecules) and endocannabinoids (anandamide and 2-arachidonoylglycerol). Eicosanoids 




inflammatory processes and play a role in inflammatory bowel disease [133, 134]. 
Furthermore, endocannabinoids have been shown to activate the endocannabinoid system 
by binding to their receptors in the intestine and other cell types, resulting in protective 
effects against inflammation [135] and [136], regulation of food intake [137], and 
regulation of energy homeostasis [138]. Therefore, the dynamic CLD storage in 
enterocytes may be important in the regulation of lipid-mediated signaling pathways. 
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	 -oxidation to generate 
ATP. Although glutamine and glutamate are the major fuel sources in enterocytes [139-
141] and intestinal FAO activity is low in fed and fasted states [142, 143], emerging 
studies highlight that regulation of intestinal FAO activity has the capacity to alter 
enterocyte TAG storage and secretion. Altering FAO in the intestine may influence 
systemic FA availability, which could alter postprandial blood TAG levels and/or energy 
balance. 
 
1.3.2.4 CLD synthesis 
The method of CLD biogenesis in enterocytes is thought to be the result of TAG 
accumulation within the ER leaflet. The mechanism through which TAG is partitioned to 
chylomicron synthesis or CLD synthesis is unknown however may be influenced by 





1.3.2.5 CLD catabolism 
In enterocytes, the size and number of CLDs increase and then decrease over time 
after dietary fat is consumed [126]. This depletion of CLDs over time suggests active 
lipolysis during dietary fat absorption. In addition, an in vitro experiment showed that the 
cytoplasm exhibits the highest lipolytic activity compared to other fractions in Caco-2 
cells [144], indicating that CLD catabolism is an important function of intestinal lipid 
metabolism. CLD catabolism may regulate the quantity and rate at which dietary fat is 
absorbed. 
1.3.2.5.1 Adipose Triglyceride Lipase 
Intestine-specific Atgl-deficient (iAtgl-deficient) mice were generated to 
investigate the role of ATGL in intestinal TAG metabolism and dietary fat absorption 
[145].  iAtgl-deficient mice have reduced TAG hydrolase activity in enterocytes from the 
proximal small intestine and increased TAG storage in CLDs compared with wild-type 
mice fed either chow or a high fat diet. However, iAtgl-deficient mice have similar TAG 
secretion from enterocytes and no fat malabsorption compared to wild-type mice. iAtgl-
defici    	  
   
 	 
           	
	  
regulating fatty acid oxidation (FAO), oxidative stress response, and cholesterol 
absorption in enterocytes compared to wild-             




well as their delayed cholesterol absorption. Overall, these results suggest that intestinal 
ATGL directs FAs released from TAG stored in CLDs towards oxidation mediated by 
   activation, and is not directly involved in CM synthesis for TAG secretion into 
circulation.  
 1.3.2.5.2 Comparative Gene Identification-58 
Intestine-specific Cgi-58-deficient (iCgi-58-deficient) mice have a significant 
reduction in intestinal TAG hydrolase activity, which results in massive TAG storage in 
CLDs in enterocytes compared to wild-type mice when fed chow or a high fat diet [146]. 
Unlike iAtgl-deficient mice, the TAG accumulation in enterocytes of iCgi-58-deficient 
mice leads to steatorrhea, indicating fat malabsorption. In addition, iCgi-58-deficient 
mice have lower postprandial blood TAG levels and reduced intestinal FAO activity 
compared to wild-type mice. These results suggest that CGI-58 is involved in mobilizing 
FAs stored in CLDs that are used for both secretion and oxidation. Recently, lipid droplet 
protein 1, a homolog of CGI-58, was identified in enterocytes of C. elegans and found to 
activate lipolysis by binding to ATGL during fasting [102]. 
 
1.3.2.5.3 Hormone Sensitive Lipase 
HSL is expressed along the length of the intestine in mice and primarily regulates 
intestinal cholesterol metabolism. Whole body Hsl-deficient mice have mild reductions in 
DAG hydrolase activity in the intestine but totally abolished CE hydrolase activity [147]. 




study the role of HSL in intestinal lipid metabolism [148]. iHSL-deficiency has little 
effect on TAG metabolism in the intestine. iHSL-deficient mice have similar TAG 
secretion into circulation and intracellular lipid species (including TAG, DAG, FA and 
PL) in enterocytes compared to wild-type mice. However, HSL-deficiency has a 
significant effect on intestinal cholesterol metabolism [148]. iHSL-deficient mice have 
higher levels of CEs, enhanced cholesterol uptake and reduced cholesterol biosynthesis in 
enterocytes compared to wild-type mice. These results suggest that in the intestine HSL is 
not required for TAG metabolism, but plays an important role in CE hydrolysis, which is 
required for normal intestinal cholesterol metabolism. 
 
1.3.2.5.4 Monoacylglycerol Lipase 
Several mouse models with altered Mgl expression have been generated to study 
the role of this enzyme in intestinal lipid metabolism. Whole body Mgl-deficient mice 
have significantly less MAG hydrolase activity and massive accumulation of MAG 
species in multiple tissues, including small intestine [149, 150]. Whole body Mgl-
deficient mice are either leaner compared to wild-type mice fed either a low or high fat 
diet [149], or of similar body weight with improved glucose tolerance and insulin 
sensitivity [150]. In addition, these mice display blunted intestinal TAG secretion without 
fat malabsorption, as determined by fecal fat content [149]. They also have reduced 
mRNA levels of genes involved in the G3P pathway and increased levels of genes 
involved in the MGAT pathway in enterocytes. Overall, the alterations in lipid 




glucose and insulin sensitivity phenotype observed in these models. Mice with intestine-
specific overexpression of MGL (iMgl overexpression mice) have higher intestinal MGL 
activity, resulting in decreases in MAG species in the intestine compared to wild-type 
mice [151]. iMgl overexpression mice are hyperphagic and have reduced energy 
expenditure, which contributes to increased susceptibility to obesity when fed a high fat 
diet. This phenotype is probably due to altered endocannabinoid signaling in the intestine 
since iMgl overexpression mice have little changes in intestinal lipid metabolism. 
Intestinal TAG synthesis, metabolism of MAG into different lipid species, and intestinal 
FAO activity are similar in iMgl overexpression mice compared to wild-type mice. 
However, iMgl overexpression mice have significantly greater TAG accumulation in the 
intestine compared to wild-type mice when fed a high fat diet, but do not have fat 
malabsorption, as determined by fecal fat content. Whether this intestinal TAG 
accumulation has effects on dietary fat absorption or contributes to the obese phenotype 
is unclear. 
 
1.3.2.5.5 Putative methods of CLD catabolism 
1.3.2.5.5.1 Carboxylesterase 
Members of the carboxylesterase family are putative or potential lipases. 
Carboxylesterase 2 is a (Ces2) is a highly expressed esterase in the liver and the intestine 




overexpressing Ces2 have increased TAG hydrolysis [153]. Members of the Ces2 family 
have been identified on intestinal CLDs [96, 127] and [95] however the role of Ces2 in 
the intestinal lipid metabolism has not been investigated. 
 
1.3.2.5.6 Autophagy 
CLDs are catabolized in the enterocyte through autophagy. Lipophagy is 
stimulated in Caco-2 cells in response to treatment with lipid micelles, as determined by 
the co-localization of TAG and components of autophagy machinery using confocal 
microscopy [154]. Although little is known about mechanistic activation and regulation 
of lipophagy in enterocytes, inhibition of autophagy initiators/mediators by miRNA and 
drug inhibition of LAL result in an increase in TAG storage in CLDs in Caco-2 cells. 
Together these results highlight that lipophagy is active and regulates intestinal CLD 
metabolism during dietary fat absorption. 
 
1.4 Methods for identifying CLD associated proteins 
Methods for identifying CLD associated proteins by either targeted or global 
proteomic approaches vary from study to study based on cell type of interest and 
endpoint, however have some consistent key features. Briefly, cells are isolated and lysed, 
CLDs are isolated via centrifugation, and proteins are identified by Western Blot or 
tandem mass spectrometry analysis. Identifying proteins associated with CLDs help 
identify regulators of CLD metabolism and expand the model of the role of CLDs in cell 




1.4.1 Introduction to identifying CLD associated proteins 
There are multiple methods for identifying proteins which associate with CLDs. 
In general, these methods fall into one of two categories, targeted and global proteomic 
approaches. Both of these approaches depend on isolation of CLDs without 
contamination of associated organelles, associated membranes, or non-CLD lipid 
containing particles. 
 
1.4.2 Isolation of CLD associated proteins 
To identify CLD associated proteins, cells are harvested under conditions where 
CLDs are present. The cells are lysed using various lysis methods based on cell type as 
described in [155].  The method of cell lysis and homogenization is dependent on the 
CLD size and cell type. A French Press or nitrogen bomb can be used to disrupt cells. 
Excess force or mechanical shearing may disrupt very large CLDs as found in adipocytes.  
The low density of CLDs allows the organelles to float in an aqueous layer after 
centrifugation. The speed at which cells are centrifuged is dependent on CLD size. Larger 
CLDs may be isolated at much slower speeds than smaller CLDs. In the case of 
lipoprotein producing tissues such as enterocytes and hepatocytes, a slower centrifugation 
step may allow for the separation of CLDs from lipoprotein sized contaminating particles. 
To identify bona fide CLD associated proteins, some investigators wash the isolated CLD 
fraction to remove contaminating membranes. This washing process has been shown to 
result in the removal of both contaminating proteins as well as reduce the level of bona 




precipitated and prepared for mass spectrometry analysis [Reviewed in[157]] Once a 
protein is identified associated with the CLD fraction by mass spectrometry analysis, the 
localization of the protein to the CLD should be confirmed using imaging techniques. 
 
1.4.3 Proteomics methods 
Proteomic methods for identifying CLD associated proteins fall into two general 
categories, targeted and global proteomics. 
 
1.4.3.1 Targeted approach 
CLD associated proteins can be identified through a targeted proteomic approach. 
This approach involves the analysis of isolated CLD associated proteins by Western Blot 
analysis. This approach is cost effective, relatively simple, and does not require special 
equipment or analysis software. The downside to a targeted approach is the analysis is 
limited by previous knowledge of proteins which are thought to play a role in CLD 
metabolism or localize to CLDs. 
 
1.4.3.2 Global approach 
CLD associated proteins can be identified through a global proteomic approach. 
This approach involves the analysis of CLD associated proteins by mass spectrometry 
analysis. This approach is more complex and requires specialized software and analysis 




particularly with modern high resolution mass spectrometers. Within the category of 
global proteomics there are two sub classifications, labeled and label free proteomics. 
Several labeling methods exist [158] which revolves around using stable isotopes to label 
amino acids to quantitatively compare levels of proteins in two or more treatment groups. 
Alternatively, quantitative levels of CLD associate proteins can be determined using label 
free proteomic approach [159]. This approach utilizes normalization software to 
determine the relative levels of a protein in a sample. 
 
1.4.4 Confirmation of CLD associated proteins by imaging 
Recent advances in imaging techniques have expanding upon the ability to 
visualize CLDs under different physiological conditions and resolutions. Commonly used 
microscopy techniques to visualize lipids are fluorphore labeled lipid (ex. BODIPY 
labeling of fatty acids), Coherent anti-stokes ramen scattering spectroscopy (CARS), and 
transmission electron microscopy. [Reviewed in [160]]. Each technique has benefits and 
limitations which should be taken into consideration when interpreting results. A number 
of techniques have been employed to visualize the localization of proteins to CLDs 
including conjugating proteins to fluorescent tags and conjugating proteins to 
fluorescently or gold labeled antibodies for confocal or TEM analysis respectively. High 






1.5 Recent discoveries and new mysteries of CLD associated proteins 
1.5.1 General observation of newly identified CLD associated proteins 
A significant body of work has been generated regarding the identification of new 
CLD associated protein.  Newly identified CLD associated proteins are associated with a 
wide range of biological processes and metabolic pathways.  These proteins include 
various mitochondrial, ER, chaperone, membrane trafficking, and carbohydrate 
metabolism related proteins. Non-lipid related proteins have been identified in CLD 
proteomic profiles from multiple species and cell types [96, 156, 161-167]. The 
identification of the roles of these non-lipid related proteins on the CLD is currently an 
understudied and underexplored area of research within the field of CLD biology. 
 
1.5.2 Newly identified CLD associated proteins in enterocytes 
The proteomes of isolated CLDs derived from Caco-2 cells and mouse 
enterocytes have been analyzed using a tandem mass spectrometry approach [95, 96, 127] 
and have been previously reviewed [94]. These studies identified both known and novel 
CLD associated proteins. Proteins were categorized based on their gene ontology into 
lipid related and non-lipid related proteins. Within the lipid related category, proteins fall 
into various sub groupings including: modifiers of FAs, PL synthesis enzymes, lipid 
transporters, and steroid synthesis enzymes (Table 1-1). Several of these proteins were 
confirmed on the CLD through imaging techniques, including 3-beta-hydroxysteroid 





hydroxysteroid dehydrogenase type 2 (DHB2) [95], and LPCAT2 [95, 127].  It is 
currently unclear what function many of these proteins serve on the CLD; however, the 
presence of these proteins can be used to generate several intriguing hypotheses. 
 
1.6 Effects of obesity on dietary fat absorption 
The effect of obesity on intestinal lipid metabolism is currently unclear, but may be 
dysregulated by obesity and associated diseases (recently reviewed [2]). Much of the 
research on obesity and blood fat levels have been conducted in the fasted state, however 
after work done by Zilversmit et al [168] which correlated increased post prandial 
response with an increased risk for atherosclerosis, more attention has been paid to blood 
fat in response to a meal. It is often to distinguish between the effect of obesity, and its 
comorbidity insulin resistance, on post prandial lipidemia.\ 
 
1.6.1 Whole animal/ physiological consequences 
Obesity is associated with dyslipidemia in the post prandial state which has been 
suggested as a risk factor for coronary artery disease [169]. The small intestine 
contributes to blood lipid levels in the post prandial state by secreting chylomicrons. The 
level of fat in the blood after a meal is a balance between the secretion of lipoproteins and 





Obese subjects with high levels of visceral adipose tissue had a prolonged or 
higher postprandial triglyceride response compared to lean subjects [170-173]. The 
authors conclude that the postprandial response was due to in part by the contributions of 
liver lipoproteins [170]. 
 
1.6.2 Enterocyte specific consequences 
Obesity affects lipid metabolism in enterocytes. Duodenal explants from insulin 
resistant obese patients had a decreased triglyceride rich lipoprotein production compared 
to insulin sensitive obese patients [174]. DIO mice had similar TAG content in intestinal 
villi in response to a dietary fat challenge as determined by CARS microscopy compared 
to lean mice. Additionally, DIO mice have decreased rate of TAG secretion in response 
to a dietary fat challenge [175, 176].  
Chronic high-fat diet consumption in mice results in DIO and alters intestinal 
CLD metabolism. DIO mice have a reduced TAG secretion rate in response to dietary fat 
compared to lean mice [4] and [197]. In the fed state, DIO mice have abundant TAG 
storage in CLDs within enterocytes, but after a six hour fast this TAG storage is 
significantly reduced. In DIO mice given an acute dietary fat challenge, mRNA levels of 
genes involved in lipolysis (Atgl and Hsl) are significantly reduced compared to before 
the challenge [4]. This is a response to dietary fat that does not occur in lean mice. These 
results suggest that DIO induces adaptations in CLD metabolism resulting in decreased 






Identifying regulators of intestinal CLD metabolism can provide potential targets 
for the prevention and treatment for chronic diseases associated with dyslipidemia 
including obesity, Type II Diabetes, and cardiovascular disease (Pirillo 2014) (Patsch 
1992). The small intestine is the source of chylomicrons in the post prandial state. The 
balance of dietary TAG storage and secretion may regulate post prandial TAG levels. The 
proteins that associate with CLDs regulate CLD metabolism and TAG mobilization. 
Identifying proteins that associate with CLDs and regulate CLD metabolism are potential 
targets for regulating chylomicron lipidation and post prandial hypertriglyceridemia. A 
few of the outstanding questions regarding the role of CLDs, and associated proteins in 
the regulation of dietary fat absorption that this thesis intends to address are:  
1) What proteins associated with CLDs in enterocytes in response to a dietary fat 
challenge? (Chapter 2). 
2) What effect does obesity have on CLDs and associated proteins? (Chapter 3) 




Table 1-1 Proteins identified by proteomic analysis associated with CLDs from 
enterocytes 
.Gene 
symbol Protein name Biological pathway Reference 
CYB5R3 NADH–cytochrome b5 reductase 3 Cholesterol metabolism 95, 96, 127 
DHCR7 7-Dehydrocholesterol reductase Cholesterol metabolism 127 
NSDHL 
NAD(P)H steroid dehydrogenase-like 
protein Cholesterol metabolism 95, 127 
ACSL3 Long chain acyl-CoA synthetase 3 Fatty acid metabolism 95, 127 
ACSL4 Long chain acyl-CoA synthetase 4 Fatty acid metabolism 127 
ACSL5 Long chain acyl-CoA synthetase 5 Fatty acid metabolism 95, 96 
ECHS1 Enoyl-CoA hydratase, mitochondrial Fatty acid oxidation 127 
Hadh Hydroxyacyl-coenzyme A dehydrogenase Fatty acid oxidation 96 
Ugt1a7c UDP-glucuronosyltransferase 1–7C Hormone metabolism 96 
Bpnt1 3(2), 5-bisphosphate nucleotidase 1 Hydrolase 96 
Ces2a Pyrethroid hydrolase Hydrolase 96 
Ces2c Acylcarnitine hydrolase Hydrolase 96 
Ces2e Pyrethroid hydrolase Hydrolase 96 
EPHX1 Epoxide hydrolase 1 Hydrolase 127 
Ephx2 Bifunctional epoxide hydrolase 2 Hydrolase 96 
LDAH Lipid droplet-associated hydrolase  Hydrolase 95, 127 
CGI-58 Comparative gene identification-58 
Lipid droplet 
metabolism 127 
FAF2 FAS-associated factor 2 
Lipid droplet 
metabolism 95, 127 
Lipe Hormone-sensitive lipase 
Lipid droplet 
metabolism 96, 128 
PLIN2 Perilipin 2/ADRP 
Lipid droplet 
metabolism 95, 127, 128, 129 
PLIN3 Perilipin 3/TIP47 
Lipid droplet 
metabolism 95, 96, 127, 129 
PNPLA2 
Patatin-like phospholipase domain-
containing protein 2 
Lipid droplet 
metabolism 95, 127, 128 
B4galnt2 
Beta-1, 4 N-acetylgalactosaminyltransferase 
2 Lipid glycosylation 96 
Scp2 Non-specific lipid-transfer protein Lipid metabolism 96 
Mogat2 Monoacylglycerol: acylCoA transferase 2 Lipid synthesis 128 
Clint Clathrin interactor 1 Lipid transport 96 
Dbi 
Diazepam binding inhibitor, Acyl-CoA-
binding protein Lipid transport 96 
Fabp1 Fatty acid-binding protein,  liver Lipid transport 96 
Fabp2 Fatty acid-binding protein, intestinal Lipid transport 96 
ANXA2 Annexin A2 Lipoprotein metabolism 96, 127 





APOA4 Apolipoprotein A-IV Lipoprotein metabolism 96, 127 
Apob Apolipoprotein B Lipoprotein metabolism 96 
APOE Apolipoprotein E Lipoprotein metabolism 127 
MGLL Monoglyceride lipase Lipoprotein metabolism 95, 127 
MTTP Microsomal triglyceride transfer protein Lipoprotein metabolism 95, 96, 127, 128 
P4HB Protein disulphide-isomerase Lipoprotein metabolism 95, 96, 127 
ANXA4 Annexin A4 Membrane metabolism 96, 127 
ELMOD2 ELMO domain-containing protein 2 Miscellaneous 127 
DHRS1 
Dehydrogenase/reductase SDR family 
member 1 
Oxidation-reduction 
process 95, 96, 127 
HSPA8 Heat-shock cognate 71 kDa protein 
Phospholipid 
metabolism 96, 127 
LPCAT2 Lysophosphatidylcholine acyltransferase 2 
Phospholipid 
metabolism 95, 127 






Atp5a1 ATP synthase subunit alpha, mitochondrial 
Regulation of lipid 
metabolism 96 
Atp5b ATP synthase subunit beta, mitochondrial 
Regulation of lipid 
metabolism 96, 127 
Cat Catalase 
Regulation of lipid 
metabolism 96 
Golm1 Golgi membrane protein 1 
Regulation of lipid 
metabolism 96 
Adh1 Alcohol dehydrogenase 1 Retinal metabolism 96 
Aldh1a1 Retinal dehydrogenase 1 Retinal metabolism 96 
DHRS3 Short-chain dehydrogenase/reductase 3 Retinal metabolism 95, 127 
Rbp2 Retinol-binding protein 2 Retinal metabolism 96 
RDH10 Retinol dehydrogenase 10 Retinal metabolism 95, 127 
SGPL1 Sphingosine-1-phosphate lyase 1 
Sphingolipid 
metabolism 127 
Cyb5a Cytochrome b5 Steroid metabolism 96 
Cyp2b10 Cytochrome P450 2B10 Steroid metabolism 96 
HSD17B11 Oestradiol 17- -dehydrogenase 11 Steroid metabolism 95, 96, 127 
HSD17B2 Estradiol 17-beta-dehydrogenase 2 Steroid metabolism 95 
HSD17B7 3-Oxo-steroid reductase Steroid metabolism 95, 127 
HSD3B1 3- -Hydroxysteroid dehydrogenase Steroid metabolism 95, 127 
Sult1b1 
Sulfotransferase family cytosolic 1B 
member 1 Steroid metabolism 96 
LSS Lanosterol synthase Sterol metabolism 95, 127 
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CHAPTER 2. CHARACTERIZATION OF THE PROTEOME OF CYTOPLASMIC 
LIPID DROPLETS IN MOUSE ENTEROCYTES AFTER A DIETARY FAT 
CHALLENGE 
2.1 Abstract 
Dietary fat absorption by the small intestine is a multistep process that regulates the 
uptake and delivery of essential nutrients and energy. One step of this process is the 
temporary storage of dietary fat in cytoplasmic lipid droplets (CLDs). The storage and 
mobilization of dietary fat is thought to be regulated by proteins that associate with the 
CLD; however, mechanistic details of this process are currently unknown. In this study 
we analyzed the proteome of CLDs isolated from enterocytes harvested from the small 
intestine of mice following a dietary fat challenge. In this analysis we identified 181 
proteins associated with the CLD fraction, of which 37 are associated with known lipid 
related metabolic pathways. We confirmed the localization of several of these proteins on 
or around the CLD through confocal and electron microscopy, including perilipin 3, 
apolipoprotein A-IV, and acyl-CoA synthetase long-chain family member 5. The 
identification of the enterocyte CLD proteome provides new insight into potential 





Dietary fat is the most energy dense macronutrient consumed and is required for 
the absorption of essential fatty acids and other lipophilic nutrients including fat soluble 
vitamins. However, when present in excess, dietary fat increases the risk for chronic 
diseases such as cardiovascular disease and obesity [1-4]. Therefore, understanding the 
regulators of dietary fat absorption and metabolism is important for both the promotion of 
health and prevention of disease.  
Dietary fat absorption by the small intestine is a multistep process. 
Triacylglycerol (TAG) is hydrolyzed by pancreatic lipase in the intestinal lumen 
producing monoacylglycerol and free fatty acids. These digestive products are taken up 
by the absorptive cells of the intestine, enterocytes, where they are rapidly resynthesized 
to TAG. The TAG is then packaged in the core of a chylomicron for systemic delivery of 
nutrients throughout the body [3,5,6]. Alternatively, when fatty acids are present in 
excess, the newly synthesized TAG may be incorporated into cytoplasmic lipid droplets 
(CLDs) within enterocytes. The size and number of CLDs within enterocytes increases 
and then decreases after consumption of dietary fat [7]; however, the factors that regulate 
CLD synthesis and catabolism within enterocytes are relatively unknown.  The 
partitioning of TAG into chylomicrons or CLDs is important for determining the amount 
and rate of fatty acids delivered systemically. Therefore, identification of factors that 
regulate enterocyte CLD metabolism is important for understanding the overall process 




Proteins that associate with CLDs in various cell types have been shown to 
regulate the synthesis and catabolism of CLDs [8-11]. Recently, our laboratory identified 
two CLD associated proteins, perilipin 2 (Plin2) and perilipin 3 (Plin3), on CLDs within 
enterocytes after a dietary fat challenge [12]. These well-established CLD associated 
proteins are thought to regulate lipolysis. In addition, mice deficient in mediators of 
lipolysis, including adipose triglyceride lipase [13] and abhydrolase domain containing 5 
[14], have altered catabolism of CLDs in enterocytes. These results strongly suggest CLD 
associated proteins regulate the synthesis and catabolism of CLDs in enterocytes. The 
identification of additional CLD associated proteins within enterocytes has the potential 
to establish novel mediators of dietary fat absorption.  
The objective of this study was to identify CLD associated proteins in enterocytes 
after a dietary fat challenge. To fulfill this objective, we isolated CLDs from the small 
intestine of mice two hours after an oil bolus and identified proteins involved in the 
regulation of lipid trafficking and metabolism using a global proteomic approach. We 





2.3 Materials and methods 
2.3.1 Ethics statement 
We conducted the study in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institute of Health. 
The protocol was approved by the Purdue Animal Care and Use Committee (PACUC# 
1111000154). All effort was made to minimize pain and suffering of mice and the 
number of mice used. 
 
2.3.2 Mice 
C57BL/6 male mice from an in-house breeding colony were used for this study. 
The mice were maintained on a chow diet (PicoLab 5053, Lab Diets, Richmond, IN, 
USA) that consisted of 62.1% of calories from carbohydrate (starch), 24.7% from protein, 
and 13.2% from fat. The mice were housed in a temperature and humidity controlled 
facility with a 12 hour light/dark cycle (6AM/6PM) with ad libitum access to food and 
water. 
 
2.3.3 Mouse procedure for lipid droplet isolation and proteomic analysis 
Four, 5 month old male C57BL/6 mice were fasted for 4 hours at the beginning of 




the oil bolus, the mice were euthanized via CO2 asphyxiation. The small intestine was 
excised and divided into five equal length segments in relation to the stomach and labeled 
sections 1-5. Segments 2 and 3, representing the jejunum, were used for analysis. 
 
2.3.4 Enterocyte Isolation 
Enterocytes were isolated from sections 2 and 3 of the small intestine as 
previously described [12,15]. Briefly, the intestinal sections were washed in tissue buffer 
(Hank's Balanced Salt Solution with 25 mM HEPES and 1% fetal calf serum) and then 
placed in isolation buffer (Calcium and magnesium free Hank's Balanced Salt Solution 
with 1.5mM EDTA). The intestine segments were incubated for 15 minutes at 37° C with 
rotation. The sample was mixed briefly (vortexed) and the supernatant containing 
enterocytes was removed and saved. The process was repeated and the supernatants 
containing isolated enterocytes were combined. 
 
2.3.5 CLD isolation 
CLDs were isolated from enterocytes using a previously established sucrose 
gradient ultracentrifugation protocol [16]. Enterocytes were lysed in ice cold sucrose lysis 
buffer (175mM sucrose, 10 mM HEPES and 1 mM EDTA pH 7.4). Cells were disrupted 
by passing through a 27 gauge, 1 inch needle, eight times. The resulting two mLs of cell 




20,000 x g at 4   C for two hours. After centrifugation, the sample was frozen at -80  C. 
The frozen sample was sliced into seven sequential fractions which were approximately 1 
cm in length. 
2.3.6 TAG and protein analysis 
TAG concentration of each fraction was determined using an L Type TG M assay 
(Wako Diagnostics, Richmond VA, USA). Protein concentration of each fraction was 
determined by a BCA assay (Thermo Scientific, Rockford IL, USA). Additionally, a 
Western Blot analysis was performed on each fraction.  Briefly, samples from the 
isolated fractions were delipidated using 10% sodium dodecyl sulfate, separated by 
polyacrylamide gel electrophoresis, and transferred to a PVDF membrane. The 
membranes were probed overnight at 4  C with antibodies for Plin3 (a gift from Dr. Perry 
Bickel at the University of Texas Southwestern, Dallas TX, USA), glyceraldehyde 3-
phosphate dehydrogenase (Gapdh) (Abcam, Cambridge MA, USA), or calnexin (Cnx) 
(Santa Cruz Biotechnology, Dallas TX, USA). These proteins were used as markers for 
the CLD, cytosolic, or membrane fractions, respectively. The blots were then probed with 
a LI-COR IR DYE 800CW secondary antibody and imaged using Odyssey CLx Infrared 
imaging system (LI-COR Biosciences, Lincoln NE, USA). 
 
2.3.7 In solution digestion and LC MS/MS  
In preparation for proteomic analysis, the isolated CLD fractions were delipidated 




protein pellet was denatured using 8M urea and 10 mM DTT for 1.5 hours at 37°C. The 
sample was digested for 12 hours using trypsin (Sigma-Aldrich, St. Louis MO, USA) 
using a ratio of 1 µg trypsin to 50 µg protein. The reaction was quenched using 
trifluoroacetic acid. Tryptic peptides were separated on a nanoLC system (1100 Series 
LC, Agilent Technologies, Santa Clara, CA). The peptides were loaded on the Agilent 
300SB-C18 enrichment column for concentration and the enrichment column was 
switched into the nano-flow path after five minutes. Peptides were separated with a C18 
reversed phase ZORBAX 300SB-C18 column. The column was connected to the 
emission tip and coupled to the nano-electrospray ionization (ESI) source of the high 
resolution hybrid ion trap mass spectrometer LTQ-Orbitrap LX (Thermo Fisher Scientific, 
Waltham MA, USA). The LTQ-orbitrap mass spectrometer was operated in the data-
dependent positive acquisition mode in which each full MS scan (30.000 resolving power) 
was followed by six MS/MS scans where the six most abundant molecular ions were 
selected and fragmented by collision induced dissociation (CID) using a normalized 
collision energy of 35%.. 
 
2.3.8 Data analysis and bioinformatics 
The peak list files containing MS and MS/MS data were analyzed using 
MaxQuant version 1.4.08[17]. For protein identification, the MS/MS data was searched 
against the Uniprot protein database which includes the Swissprot (manually annotated 
and reviewed) and TrEMBL (automatically annotated and not reviewed) databases [18]. 




peptide search algorithm that is incorporated in the MaxQuant platform [19]. The search 
was conducted using the following settings: trypsin cleavage with a maximum of two 
missed cleavages, fixed modification of iodoethanol addition to cysteine, variable 
modification of oxidation of methionine. The MS mass tolerance was set at 4.5 ppm with 
a maximum number of five modifications. The false discovery rate was set at 0.01 for 
proteins and peptides and was run against a decoy revert database. Peptides required a 
minimum length of seven amino acids. The MS/MS tolerance was set at 0.1 Da for 
protein identification. The minimum score for modified and unmodified peptides was set 
at forty. At least two peptides were required for protein identification. 
The bioinformatics and statistical package Perseus 1.4.1.3 was used to analyze the 
MaxQuant output. Contaminants identified by Perseus, such as keratin, were removed 
from the analysis. For label free quantitation (LFQ), the intensity for each protein was 
transformed log2(x) and samples who had a peptide intensity below the level of detection 
were assigned a value of 14. We limited the analysis to proteins which were identified in 
at least 3 out of the 4 biological replicates.  
Proteins identified were clustered by their Gene Ontology (GO) Term based on 
biological process or molecular function using the Database for Annotation, Visualization 
and Integrated Discovery (DAVID) v 6.7 [20,21]. Visualization of protein interactions 
was accomplished using STRING version 9.1[22]. We used the confidence view with a 
score of 0.4, indicating a medium confidence level. We did not limit the number of 





2.3.9 Immunofluorescence Imaging 
Four, C57BL/6 male mice were fasted for 4 hours at the beginning of the light 
cycle and then administered a 200 µl olive oil bolus.  A small (5mm) section of the 
jejunum was harvested from the mice two hours after the dietary fat challenge and was 
frozen in optimal cutting temperature embedding media. The tissue was stored at -80°C 
until processed by immunofluorescence microscopy. The tissue was sliced into 10 µm 
tissue sections, fixed in 2% paraformaldehyde, and permeabilized with 0.1% saponin. 
The tissue was probed with previously validated antibodies for Plin3 [23] (a gift from Dr. 
Perry Bickel at the University of Texas Southwestern, Dallas TX, USA), apolipoprotein 
A-IV (ApoA-IV) [24] (a gift from Dr. Patrick Tso from the University of Cincinnati, 
Reading OH, USA), and acyl-CoA synthetase long-chain family member 5 (Acsl5) 
(personal communication with A. Greenberg) (a gift from Dr. Andrew Greenberg from 
Tufts University, Boston MA, USA). The sections were also stained for neutral lipids 
   	
 -difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene 
(BODIPY) (Life technologies, Grand Island NY, USA), a secondary AlexaFluor antibody 
(Life technologies), and for nuclei using 300 nM DAPI (Life technologies). The sections 
were imaged using a Nikon A1R confocal microscope (Nikon Instruments Inc., Melville 
NY, USA). Image processing, co-localization analysis, and multidimensional imaging 





2.3.10 Transmission electron microscopy 
2.3.10.1 Cardiac perfusion fixation and TEM imaging of jejunum 
Two, C57BL/6 mice were fasted for 4 hours at the beginning of the light cycle. 
An oral gavage of 200 µl olive oil was administered and two hours after the oil bolus, the 
mice were anesthetized using inhaled isoflurane and perfused with 1.5% glutaraldehyde 
in 0.1M sodium cacodylate via cardiac infusion. After fixation, a sample of the jejunum 
section of the small intestine was isolated, stained with osmium tetroxide, dehydrated, 
and embedded in resin. Ultrathin sections were stained with lead citrate and uranyl 
acetate and examined using a Tecnai T20 Transmission Electron Microscope (FEI, 
Hillsboro OR, USA). 
 
2.3.10.2 TEM imaging of isolated CLDs 
A sample from the isolated CLD fraction was negatively stained using 2% w/v 
aqueous uranyl acetate. The isolated CLDs were imaged using a Tecnai T20 
Transmission Electron Microscope (FEI). 
 
2.3.10.3 Immunoelectron microscopy 
Two, C57BL/6 mice were fasted for 4 hours at the beginning of the light cycle. 
An oral gavage of 200 µl olive oil was administered and two hours after the oil bolus, the 
mice were anesthetized using inhaled isoflurane and perfused with 4% paraformaldehyde 




sample of the jejunum section of the small intestine was isolated, dehydrated, and 
embedded in resin. Ultrathin sections were probed with an antibody for Acsl5 (a gift from 
Dr. Andy Greenberg), gold conjugated secondary antibody (Ted Pella Inc. Redding, CA), 
and stained with uranyl acetate. The samples were examined using Tecnai T20 
Transmission Electron Microscope (FEI). 
 
2.4 Results 
2.4.1 Lipid accumulates in CLDs in enterocytes in response to a dietary fat challenge. 
Neutral lipids accumulate in distinct regions of the enterocyte following an acute 
olive oil bolus. Enterocytes from the jejunum section of the small intestine, two hours 
after a dietary fat challenge, were stained with osmium tetroxide and examined by 
transmission electron microscopy (Figure 1). The various fates of neutral lipids within 
enterocytes following a dietary fat challenge are identified in this image. Neutral lipids 
accumulate in large CLDs which are indicated by white asterisks. Also visible is the 
Golgi apparatus (white arrows) which contains smaller chylomicron sized particles. 
Additionally, the white areas between enterocytes contain secreted chylomicrons (black 
cross). These results highlight the complex, multistep process of dietary fat absorption. 
 
2.4.2 The CLD fraction is enriched with Plin3 and has a high TAG to protein ratio. 
Enterocyte CLDs were isolated via density gradient ultracentrifugation using a 




sliced into seven fractions, where fraction 1 contains CLDs (Figure 2a). To confirm the 
successful isolation of CLDs, the isolated fractions were subjected to Western blot 
analysis. Antibodies for Plin3, Gapdh, and Cnx, were used as markers of the CLD, 
cytosolic, and membrane fractions respectively. The CLD marker Plin3 was found in 
fractions 1, 4, 5, 6, and 7 (Figure 2c), representing the various fractions Plin3 has been 
previously described to locate [25]. Plin3 is found primarily in the cytosol when lipids are 
absent and translocate to the nascent CLD in the early stages of CLD formation. Gapdh 
was used as a cytosolic marker and was found primarily in the cytosolic fractions 
(fractions 2-6). In addition, Gapdh was notably absent in fraction 1. Cnx was used as a 
marker for membranes and found primarily in fraction 7. To validate the presence of 
CLDs, the TAG to protein ratio of each fraction was examined (Figure 2b). Fraction 1 
contained a high concentration of TAG compared to protein, indicating the presence of 
CLDs. Fraction 1 was also examined using negative staining electron microscopy which 
showed an abundance of round, CLD sized particles (Figure 2d). This data suggests that 
CLDs were successfully isolated from mouse enterocytes. 
 
2.4.3 Proteins were identified in the CLD fraction through LC MS/MS 
To identify proteins that associate with the CLD fraction, we utilized a shotgun 
proteomic approach. Through high resolution tandem mass spectroscopy, we identified 
181 proteins in at least 3 out of the 4 biological replicates (Data not shown). Proteins 
were identified by comparing the MS/MS spectra against the Uniprot database. The 




Using Maxquant’s LFQ [26], the relative abundance of each protein within each sample 
was identified. It should be noted that the LFQ intensity is the result of multiple factors, 
including the abundance of the protein within the sample and the ability of the peptides to 
be ionized and detected.  To identify the function of the proteins, we used the functional 
annotation tool in DAVID. The Gene Ontology (GO) terms of molecular function and 
biological process associated with each protein was identified and then GO terms were 
clustered into broader classifications as described in Table 1. The percentage of proteins 
categorized within broader classifications is found in Figure 3. On several occasions, the 
GO terms associated with a protein would fall under multiple broader classifications. 
Under these circumstances, a manual analysis of the protein’s function was conducted 
using the Uniprot and NCBI databases. Based on the quantity and quality of reported 
protein function, the protein was assigned into the most appropriate GO term and broader 
classification. 
 
2.4.4 Some identified proteins in the CLD fraction are associated with known lipid 
metabolism related functions 
Using DAVID’s functional analysis tool, 19% of the proteins identified in the 
CLD fraction were found to be associated with a biological process or molecular function 
related to lipid metabolism. The relative abundance of these proteins was determined by 
Maxquant’s LFQ (Table 2). Approximately half of these proteins have been identified in 
other CLD proteomic studies from diverse cell types (Table 2). We specifically 




intestinal cell model through proteomic analysis. A map of predicted interactions was 
generated using a STRING analysis (Figure 4) [22]. The resulting network shows several 
protein clusters including proteins responsible for lipoprotein synthesis and modifiers of 
fatty acids. 
2.4.5 Immunofluorescence imaging of proteins identified in the CLD fraction supports 
their CLD localization 
To confirm the localization of ApoA-IV and Acsl5 on or around CLDs, we 
probed intestinal sections with antibodies for these proteins from four, male C57BL/6 
mice, two hours after a 200 µl olive oil bolus. To visualize CLDs, we stained neutral 
lipids with BODIPY (Life technologies) and used immunofluorescence staining of a 
well-established marker of enterocyte CLDs, Plin3 [12]. Due to the process of fixation, 
neutral lipids are often depleted from CLDs; therefore, where applicable, both Plin3 and 
neutral lipid staining was used to enhance our ability to detect CLDs. The first protein 
investigated was ApoA-IV, a protein known regulate intestinal lipid absorption and 
chylomicron synthesis [27,28]. To confirm the localization of ApoA-IV to the area on or 
around the CLD, the signals from Plin3 (Figure 5A) and ApoA-IV (Figure 5B) were 
merged and overlaid with signals from nuclei (blue) and neutral lipid (orange) (Figure 
5C). A region of interest was highlighted (white capped line) in Figure 5C. The intensity 
profile of all fluorescent signals along this line was generated (Figure 5D). The intensity 
signals from Plin3 and ApoA-IV overlap and form two peaks which flank the signal from 
neutral lipids. Additionally, the signal from ApoA-IV and Plin3 antibodies colocalize 




a high degree of correlation. This indicates that ApoA-IV localizes to the area on or 
around the CLD. A three dimensional volume view was generated from Z-series images 
(Figure 5E) and illustrates the localization of Plin3 and ApoA-IV to the area on or around 
the CLD forming a protein coat. The intensity profile, colocalization analysis, and 
volume view was generated using NIS- Elements C software.  
 The proteomic analysis of isolated CLDs also identified Acsl5, an enzyme that 
activates fatty acids by the addition of coenzyme A [29]. In this experiment, we were 
unable to use Plin3 as a marker for CLD due to the fact the antibodies for Acsl5 and Plin3 
were generated in the same host species, so CLDs are identified using only BODIPY. 
Intestinal sections were probed with an antibody for Acsl5 (green) (Figure 6a), stained for 
neutral lipids using BODIPY (orange) and nuclei using DAPI (blue) (Figure 6B). Acsl5 
forms distinct ring like structures on or around CLDs as indicated by the white arrows. A 
3D volume view was generated from Z series images (Figure 6C) showing the 
localization of Acsl5 to the area on or around CLDs.  Additionally, to confirm the 
localization of Acsl5 to CLDs in enterocytes following a 200 µl olive oil bolus, we 
performed immunogold labeling of ultra-thin sections of the jejunum section of the small 
intestine. An electromicrograph (Figure 6D) shows an enterocyte with large white CLDs 
present. Areas of interest are highlighted by colored arrows which correspond with 
figures 6 E-H. Acsl5 conjugated gold particles are found on the CLD surface which are 
indicated by the white arrows (Figure 6E-G). In figure 6E, Acsl5 can be seen localized to 




left hand side of the CLD. Additionally, Acsl5 can be found localized to the mitochondria 
(Figure 6H) which has been previously reported in Caco-2 cells[30,31] and liver 
McArdle-RH7777 cells[32]. 
2.5 Discussion 
To increase our understanding of the process of dietary fat absorption, we 
investigated a key step of this process, the storage of dietary fat in CLDs. Proteins 
associated with CLDs are likely involved in both the storage and trafficking of fatty acids 
as well as other cellular processes. Therefore, we analyzed the proteome of CLDs from 
enterocytes isolated from the jejunum section of the small intestine following an oil bolus 
using high resolution tandem mass spectroscopy. We identified 181 proteins associated 
with the CLD fraction (Data not shown) that are associated with a wide range of 
biological and molecular functions (Figure 3). Several of the identified proteins 
associated with lipid metabolism have been previously identified in other CLDs 
proteomic analyses from many cell types, while other identified proteins have not been 
previously reported (Table 2). Furthermore, we confirmed the localization of select 
proteins through immunohistochemistry and immunoelectron microscopy (Figures 5 and 
6).  
Of the 181 proteins identified in the CLD fraction of mouse enterocytes, thirty 
seven proteins are associated with known lipid related processes. Within this subgroup, 
twenty three proteins (62%) have been identified in CLD proteomic analyses in various 
cell types and fourteen proteins (38%) have not been previously reported in CLD 




ApoA-IV, Acsl5, and microsomal triglyceride transfer protein (Mttp), have been 
previously identified in a human cell model of enterocytes, Caco-2 cells, but not other 
cell types [33,34].  Therefore, these proteins may be unique to the CLD of enterocytes 
and serve a function on CLDs in dietary fat absorption not previously recognized. We 
confirmed the localization of ApoA-IV and Acsl5 on or around CLDs through 
immunohistochemistry and immunoelectron microscopy analysis of mouse enterocytes 
after a high fat challenge. 
ApoA-IV may play important roles in dietary fat absorption due to its localization 
on lipoproteins and CLDs [33,35]. Both lipoproteins and CLDs function as lipid storage 
vesicles and are surrounded by a phospholipid monolayer and a diverse array of proteins 
[3,36].  Many of these proteins regulate synthesis and catabolism of these similar 
structures. Therefore, the identification of common proteins on lipoproteins and CLDs is 
not surprising. We observed ApoA-IV forming a distinct ring like structure around CLDs 
and co-localizing with Plin3, an established CLD protein, through immunofluorescence 
imaging. Consistent with this result, ApoA-IV was also identified on CLDs in Caco-2 
cells via immunoelectron microscopy [33].  Although the precise function of ApoA-IV 
on lipoproteins is not clear, expression of ApoA-IV regulates lipoprotein synthesis and 
satiety. When over-expressed, ApoA-IV increases TAG secretion from the liver and 
intestine, by increasing the amount of lipid packaged on apolipoprotein B (ApoB) 
containing lipoprotein particles [37-40]. Furthermore, ApoA- IV regulates feeding 
behavior by trafficking to the brain and serving as a satiety signal [41]. Current 
knowledge of ApoA-IV’s role in lipoprotein metabolism can be applied to the formation 




synthesis and/or regulate satiety through sequestration of the protein on the CLD.   These 
hypotheses remain to be tested.  
Although the identification of lipoprotein associated proteins in the CLD fraction 
is not surprising, it is important to consider the potential for contamination of the CLD 
fraction by lipoproteins. To minimize contamination of the CLD fraction by smaller, lipid 
containing particles the samples were centrifuged at a relatively low speed (20,000 x g). 
Smaller lipid containing particles such as lumenal lipid droplets, pre-chylomicron 
transport vesicles, and chylomicrons, are isolated at much faster centrifugation speeds, 
106,000 x  g [42], 100,000 x g [43], and 197,000 x g [44], respectively. Despite efforts to 
minimize lipoprotein contamination, we still identified several proteins which are 
established for association with lipoproteins including ApoA-IV, ApoB, and Mttp.  This 
observation is consistent with other CLD proteomic analyses from a range of cell types 
that have also identified lipoprotein associated proteins [33,45],  including cell types not 
known to produce lipoproteins [46,47]. Furthermore, ApoA-IV and ApoB were 
demonstrated to localize to CLDs through immunoelectron microscopy in Caco-2 cells 
[33] and hepatocytes [48] respectively. Together, these results support that a protein may 
be associated with both lipoproteins and CLDs. 
Acsl5 may play a role in localized TAG synthesis on CLDs in enterocytes as part 
of the process of dietary fat absorption.  It was recently demonstrated in lipid challenged 
Drosophilia S2 cells that TAGs synthesis enzymes localize to CLDs including glycerol-3-
phosphate acyltransferase 4, 1-acyl-sn-glycerol-3-phsophate acyltransferase gamma, and 
diacylglycerol acyltransferase 2 [11]. In the intestine, two TAG synthesis enzymes that 




diacylglycerol acyltransferase 2 were identified as associated with CLDs by western 
blotting [49]. Additionally, Acsl enzymes activate fatty acids and channel them towards 
specific metabolic fates within cells [50]. Interestingly, other Acsl family members 
including Acsl1 [45,46], Acsl3 [33,34,46], and Acsl4 [33,46] have been identified on 
CLDs in various cell types. In particular, Acsl3 over-expression in Cos-1 cells results in 
generation and expansion of CLDs in response to fatty acids [51].  Finally, Acsl5 directs 
exogenous fatty acids toward TAG synthesis in hepatocytes [32,52]. Therefore, one 
hypothesis for the function of Acsl5 on CLDs in enterocytes is the activation of fatty 
acids for TAG synthesis; however, this hypothesis remains to be tested.  
A limitation to a proteomic approach for identifying CLD associated proteins is 
the challenge to distinguish protein contamination from other cellular organelles from 
bona fide CLD proteins in the isolated CLD fraction.  It is possible that proteins from 
other organelles associate with the CLD fraction nonspecifically during cell lysis because 
of the normal tight association of CLDs with other organelles [53]. Methods described in 
the literature for isolation of CLDs vary in how cells are lysed and the type and numbers 
of washes used. Currently there is not one commonly accepted method for CLD isolation 
to alleviate this problem. CLD isolation protocols involving multiple washing steps 
remove proteins known to associate with other organelles, as well as decrease the levels 
of well-established CLD proteins [45]. In the current study, we used a single step 
isolation protocol to preserve potentially loosely bound CLD proteins and reduce the risk 
of missing key players in CLD metabolism. However, we only included proteins 
identified in 3 of 4 biological replicates to rule out random contamination.  Due to these 




imaging to confirm the localization to CLDs in enterocytes before making firm 
conclusions.  Despite these limitations, the identification of Acsl5 on CLDs, ER, and 
mitochondria highlights that a single protein may have multiple associations in the cell. 
The protein list generated here is intended to be used as an informed, hypothesis 
generating tool to prioritize future research, not as a list of established proteins on CLDs 
in enterocytes.  
The proteins identified in the current study build upon an existing body literature 
of CLD biology, from which interesting commonalities are being observed. A key feature, 
of all CLD proteomic analyses from multiple cell types, is the identification of non-lipid 
related proteins in the CLD fraction. These proteins fall into a wide range of biological 
and molecular functions such as amino acid metabolism, carbohydrate metabolism, and 
membrane trafficking (Figure 3) [33,34,45-47,54-58]. This consistent observation has not 
been fully investigated and remains an intriguing paradox of CLD biology. Several 
hypotheses have been proposed to address this issue including the role of CLDs as 
sequestration sites [59,60] or in the regulation of membrane trafficking [61]. The 
identification of non-lipid related protein in the CLD fraction has expanded our 
perception of the CLD from a simple lipid storage site to a complex and multi-functional 
organelle [62].  
 We successfully isolated CLDs from the jejunum of mice after a dietary fat 
challenge and identified the proteome of the CLDs. Similar to previously reported CLD 
proteomic analyses, the proteins identified in the CLD fraction are associated with a wide 
range of biological processes and molecular functions. Of interest, ApoA-IV and Acsl5 




confirmed through immunofluorescence and immunoelectron microscopy. The role of 
many of these lipid related proteins on the CLD is currently unknown, however the 
proteomic analysis provides a foundation to further investigate the role of these proteins 
and advance the model of dietary fat absorption and lipid trafficking in the small intestine. 
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Table 2-1 GO Terms associated with protein classification term. 
GO terms of biological process and molecular function were grouped under broader 
classifications. Proteins were assigned into a broader classifications based on the 
associated GO terms. 
 
Classification GO_id GO Term Number of 
proteins 
Translation GO:0006412 Translation 22 
GO:0006417 regulation of translation 5 
Carbohydrate GO:0044275 cellular carbohydrate catabolic process 8 
GO:0016052 carbohydrate catabolic process 11 
GO:0044262 cellular carbohydrate metabolic process 11 
GO:0030246 carbohydrate binding 9 
GO:0016051 carbohydrate biosynthetic process 6 
Cytoskeletal GO:0030029 actin filament-based process 12 
GO:0051015 actin filament binding 5 
GO:0008092 cytoskeletal protein binding 11 
Lipid GO:0006629 lipid metabolic process 21 
GO:0044255 cellular lipid metabolic process 18 
GO:0008289 lipid binding 17 
GO:0019216 regulation of lipid metabolic process 10 
GO:0016042 lipid catabolic process 7 
GO:0005811 lipid particle 6 




GO:0008104 protein localization 18 
GO:0032880 regulation of protein localization 6 




GO:0019538 protein metabolic process 47 
GO:0071822 protein complex subunit organization 23 
GO:0042803 protein homodimerization activity 19 
GO:0006461 protein complex assembly 18 
GO:0032403 protein complex binding 17 
GO:0051246 regulation of protein metabolic process 16 
GO:0022613 ribonucleoprotein complex biogenesis 12 
RNA and 
transcription 
GO:0051252 regulation of RNA metabolic process 17 
GO:0006403 RNA localization 4 
GO:2001141 regulation of RNA biosynthetic process 15 
GO:0006396 RNA processing 14 
Redox GO:0055114 oxidation-reduction process 27 
GO:0045454 cell redox homeostasis 4 




Table 2-2 A sub group of proteins are associated with known lipid related functions. 
Thirty seven proteins associated with known lipid metabolism pathways were identified, 
of which twenty three proteins have been previously identified in other CLD proteomic 
analyses. Relative levels of the proteins were determined by LFQ and the average is 



















20.926 Alcohol dehydrogenase 1 Adh1 Q3UKA4 [45,54,55,58]   
20.006 Retinal dehydrogenase 1 Aldh1a1 P24549 [45]  




21.993 Annexin A4 Anxa4 Q7TMN7 [47] [33] 
23.367 Apolipoprotein A-I Apoa1 Q3V2G1 [45-47]  
24.529 Apolipoprotein A-IV Apoa4 Q9DBN0 [33] 
18.634 Apolipoprotein B Apob E9Q414  
19.522 
ATP synthase subunit alpha, 
mitochondrial 
Atp5a1 Q03265 [45,47]  
22.053 
ATP synthase subunit beta, 
mitochondrial 














19.926 Catalase Cat Q8C6E3 [45,64]   
18.289 Carboxylesterase 2a Ces2a Q8QZR3  
20.492 Carboxylesterase 2c Ces2c Q91WG0  
23.281 Carboxylesterase 2e Ces2e Q8BK48  
16.681 Clathrin interactor 1 Clint1 Q5SUH7  





Table 2-2: Continued 
22.653 NADH-cytochrome b5 reductase 3 Cyb5r3 Q9DCN2 [45] [33,34]  
20.515 Cytochrome P450 2B10 Cyp2b10 Q9WUD0  
21.318 Acyl-CoA-binding protein Dbi Q548W7 [47]  
19.61 Bifunctional epoxide hydrolase 2 Ephx2 Q3UQ71 [45]  
23.106 Fatty acid-binding protein, liver Fabp1 Q3V2F7 [45]  
22.526 Fatty acid-binding protein, intestinal Fabp2 Q53YP5  




Hadh Q61425 [46]  
21.474 Estradiol 17-beta-dehydrogenase 11 Hsd17b11 Q9EQ06 [45,46] [33,34]  










20.812 Nucleoside diphosphate kinase Nme2 Q01768  




19.272 Peroxiredoxin-6 Prdx6 Q6GT24 [45]  
18.859 Retinol-binding protein 2 Rbp2 Q08652  
20.936 Non-specific lipid-transfer protein Scp2 P32020 [45,46]  
19.562 





21.097 UDP-glucuronosyltransferase 1-7C Ugt1a7c Q6ZQM8  
18.177 
Transitional endoplasmic reticulum 
ATPase 
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CHAPTER 3. DIET INDUCED OBESITY ALTERS CYTOPLASMIC LIPID 
DROPLET MORPHOLOGY AND ASSOCIATED PROTEINS IN RESPONSE TO 
AN ACUTE DIETARY FAT CHALLENGE 
3.1 Abstract 
Dietary fat absorption by the small intestine is an efficient, multistep process that 
regulates the uptake and delivery of essential nutrients and energy. Fatty acids taken up 
by enterocytes, the absorptive cells of the small intestine, are resynthesized into 
triacylglycerol (TAG) and either secreted in chylomicrons or temporarily stored in 
cytoplasmic lipid droplets (CLDs). Proteins that associate with CLDs are thought to 
regulate the dynamics of TAG storage and mobilization. It is currently unclear what 
affect diet induced obesity (DIO) has on the balance between dietary fat storage and 
secretion. Specifically, there is limited knowledge of how DIO affects the level and 
diversity of proteins that associate with CLDs and regulate CLD dynamics. In the current 
study, we characterize CLDs from lean and DIO mice through histological and proteomic 
analyses. We demonstrate that DIO mice have larger intestinal CLDs compared to lean 
mice in response to dietary fat. Additionally we identified 375 proteins associated with 
CLDs in lean and DIO mice. We identify a subgroup of lipid related proteins which are 




steroid synthesis pathways, TAG synthesis, and lipolysis. This analysis expands upon our 
knowledge of the effect of DIO obesity on the process of dietary fat absorption in the 
small intestine. 
3.2 Introduction 
Enterocytes, the absorptive cells of the small intestine, are responsible for the 
uptake, repackaging, and secretion of dietary fat. In addition, enterocytes are capable of 
temporarily storing dietary fat in CLDs in response to a dietary fat challenge (Reviewed 
in [1, 2]) Dietary fat in the form of TAG is digested in the lumen of the small intestine 
producing FFA and MAG which are incorporated into mixed micelles. Mixed micelles 
interact with the brush border membrane of enterocytes and FFA and MAG are taken up 
by enterocytes. In the enterocyte FFA and MAG are resynthesized into TAG by MGAT 
and DGAT at the ER. The resulting TAG can be packaged onto a chylomicron particle 
for secretion or temporarily stored in CLDs. 
CLDs are composed of a neutral lipid core, a phospholipid monolayer, and 
associated proteins [3]. Proteins which associate with CLDs are thought to regulate the 
storage and mobilization of TAG. Proteins associated with CLDs isolated from 
enterocytes after a lipid challenge have been identified by targeted [4] and global 
proteomic [5-7] approaches. These studies have identified and confirmed members of the 
perilipin family (Plin2 and Plin3) associated with CLDs. Interestingly, these studies have 
also identified proteins associated with a wide variety of biological pathways including 




Obesity alters the process of dietary fat absorption. The effect of obesity on 
intestinal lipid metabolism is currently unclear, but may be dysregulated by obesity and 
associated diseases (recently reviewed [8]). Recent studies in high fat diet fed (non obese), 
ob/ob mice, and DIO mice have demonstrated decreased TAG secretion rates in response 
to an acute dietary fat challenge, when lipoprotein lipase has been inhibited with 
tyloxapol [9, 10]. Inhibition of lipoprotein lipase blocks the clearance of lipoproteins 
resulting in a dramatic increase in blood TAG levels. DIO alters intestinal mRNA levels 
of proteins involved in chylomicron assembly, TAG synthesis, and fatty acid trafficking 
[10]. 
Little is known on the effect of obesity on CLD morphology and associated 
proteins in enterocytes. DIO alters CLD associated proteins in adipocytes and 
hepatocytes [11, 12].Little is known on the effect of obesity on the CLD proteome in 
enterocytes. Previous studies have shown alterations in mRNA levels of proteins known 
to associate with CLDs including lipases [10] and members of the perilipin family[13]. 
Plin2 and 3 localize to CLDs in response to a dietary fat challenge, however under 
different physiological conditions. Plin3 localizes to CLDs in response to an acute dietary 
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Plin2 localizes to CLDs in response to chronic high fat feeding in a DIO mouse model 
[13]. A comprehensive analysis of proteins associated with CLDs from lean and DIO 
mice in response to an acute dietary fat challenge has not been conducted 
` To determine the effects of DIO on enterocyte CLD morphology and associated 
proteins in response to consumption of an acute dietary fat challenge, we investigated 




electron microscopy, immunofluorescence microscopy, and proteomic analysis. Based on 
previous observations [9, 10, 13] of altered TAG secretion in DIO mice in response to a 
dietary fat challenge, we hypothesized that DIO mice have altered CLD morphology and 
CLD associated proteins. 
 
3.3 Materials and methods 
3.3.1 Mice 
C57BL/6 male mice from an in-house breeding colony were used for this study. 
The mice were maintained on a chow diet (PicoLab 5053, Lab Diets, Richmond, IN, 
USA) that consisted of 62.1% of calories from carbohydrate (starch), 24.7% from protein, 
and 13.2% from fat from weaning to 5 weeks of age. The mice were housed in a 
temperature and humidity controlled facility with a 12 hour light/dark cycle (6AM/6PM) 
with ad libitum access to food and water. 
 
3.3.2 Generation of DIO mouse model 
C57BL/6 male mice were placed on a either high fat diet or low fat diet. The high 
fat diet (D12492, Research Diet, New Brunswick, NJ, USA) consists of 20% of calories 
from carbohydrates, 20% from protein, and 60% from fat. The low fat, D12492 matched 
diet (D12450J, Research Diet, New Brunswick, NJ, USA) consists of 70% of calories 
from carbohydrates, 20% from protein, and 10% from fat. The mice were maintained on 




3.3.3 Mouse procedure for lipid droplet isolation and proteomics analysis 
Five mice from the low fat diet group and 5 mice from the high fat diet group 
were     	 
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oil was administered and two hours after the oil bolus, the mice were euthanized via CO2 
asphyxiation. The small intestine was excised and divided into three equal length 
segments in relation to the stomach. The middle segment, representing the jejunum, was 
used for the analysis. 
 
3.3.4 Enterocyte isolation 
Enterocytes were isolated from the middle section of the small intestine as 
previously described [13, 14]. Briefly, the intestinal sections were washed in tissue buffer 
(Hank's Balanced Salt Solution with 25 mM HEPES and 1% fetal calf serum) and then 
placed in isolation buffer (Calcium and magnesium free Hank's Balanced Salt Solution 
with 1.5mM EDTA). The intestine segments were incubated for 15 minutes at 37°C with 
rotation. The sample was mixed briefly (vortexed) and the supernatant containing 
enterocytes was removed and saved. The process was repeated and the supernatants 
containing isolated enterocytes were combined. 
 
3.3.5 CLD isolation 
CLDs were isolated from enterocytes using a previously established sucrose 




buffer (175mM sucrose, 10 mM HEPES and 1 mM EDTA pH 7.4). Cells were disrupted 
by passing through a 27 gauge, 1 inch needle, eight times. The resulting two mLs of cell 
lysate were carefully layered with six mLs of sucrose-free lysis buffer and centrifuged at 
20,000 x g at 4°C for two hours. After centrifugation, the sample was frozen at -80°C. 
The frozen sample was sliced into seven sequential fractions which were approximately 1 
cm in length. 
 
3.3.6 In solution digestion and LC MS/MS 
In preparation for proteomic analysis, the isolated CLD fractions were delipidated 
using 2:1 chloroform methanol and proteins precipitated using ice cold acetone. The 
protein pellet was denatured using 8M urea and 10 mM DTT for 1.5 hours at 37°C. The 
sample was digested for 12 hours using trypsin (Sigma-Aldrich, St. Louis MO, USA) 
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trifluoroacetic acid. Tryptic peptides were separated on a nanoLC system (1100 Series 
LC, Agilent Technologies, Santa Clara, CA). The peptides were loaded on the Agilent 
300SB-C18 enrichment column for concentration and the enrichment column was 
switched into the nano-flow path after five minutes. Peptides were separated with a C18 
reversed phase ZORBAX 300SB-C18 column. The column was connected to the 
emission tip and coupled to the nano-electrospray ionization source of the high resolution 





MA, USA). The LTQ-orbitrap mass spectrometer was operated in the data-dependent 
positive acquisition mode in which each full MS scan (30.000 resolving power) was 
followed by six MS/MS scans where the six most abundant molecular ions were selected 
and fragmented by collision induced dissociation (CID) using a normalized collision 
energy of 35%.. 
 
3.3.7 Protein identification 
The peak list files containing MS and MS/MS data were analyzed using 
MaxQuant version 1.4.08 [15, 16]. For protein identification, the MS/MS data was 
searched against the Uniprot protein database[17]. The database was searched using the 
MASCOT search engine utilizing Andromeda as the peptide search algorithm that is 
incorporated in the MaxQuant platform [18]. The search was conducted using the 
following settings: trypsin cleavage with a maximum of two missed cleavages, fixed 
modification of iodoethanol addition to cysteine, variable modification of oxidation of 
methionine and acetylation of the N-terminal. The MS mass tolerance was set at 4.5 ppm 
with a maximum number of five modifications. The false discovery rate was set at 0.01 
for proteins and peptides and was run against a decoy revert database. Peptides required a 
minimum length of seven amino acids. The MS/MS tolerance was set at 0.1 Da for 
protein identification. The minimum score for modified and unmodified peptides was set 
at forty. At least two peptides were required for protein identification. The bioinformatics 
and statistical package Perseus 1.4.1.3 was used to analyze the MaxQuant output. 




label free quantitation (LFQ), the intensity for each protein was transformed log2(x). A 
protein was considered identified in a treatment group if it was identified in at least 3 out 
of the 5 biological replicates. 
 
3.3.8 Data analysis and bioinformatics 
The Gene Ontology (GO) Terms for biological process associated with identified 
proteins were determined using Gene Ontology Enrichment Analysis and Visualization 
Tool (GOrilla) [19, 20]. Visualization of enriched GO terms was accomplished using 
GOrilla comparing the isolated CLD proteomic profile to the entire mouse proteome 
obtained from the Uniprot protein database. The p value threshold was set at p< .01. 
Lipid related GO terms were identified and proteins associated with the lipid related GO 
terms were compiled and are here on referred to as “Lipid related proteins”. Visualization 
of protein interactions was accomplished using STRING version 10.0 [21]. We used the 
confidence view with a score of 0.4, indicating a medium confidence level. 
 
3.3.9 Immunofluorescence imaging 
Four mice from low fat diet treatment group and the high fat treatment group were 
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oil bolus. A small (5mm) section of the jejunum was harvested from the mice two hours 
after the dietary fat challenge and was frozen in optimal cutting temperature embedding 
media in 2-methyl butane cooled with dry ice. The tissue was stored at -80°C until 
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sections, fixed in 2% paraformaldehyde, permeabilized with 0.1% saponin, and blocked 
with 3% bovine serum albumin in PBS. The tissue was probed with previously validated 
antibodies for Plin3 [22] (a gift from Dr. Perry Bickel at the University of Texas 
Southwestern, Dallas TX, USA) and Plin2 [22]. The sections were also stained for neutral 
   	 
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-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene 
(BODIPY) (Life technologies, Grand Island NY, USA), a secondary AlexaFluor antibody 
(Life technologies), and for nuclei using 300 nM DAPI (Life technologies). The sections 
were imaged using a Nikon A1R confocal microscope (Nikon Instruments Inc., Melville 
NY, USA). Image processing was conducted using NIS- Elements C acquisition and 
analysis software. 
 
3.3.10 Cardiac perfusion, fixation, and transmission electron microscopy 
Three mice from low fat diet treatment group and high fat treatment group, were 
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was administered and two hours after the oil bolus, the mice were anesthetized using 
inhaled isoflurane and perfused with 1.5% glutaraldehyde in 0.1M sodium cacodylate via 
cardiac infusion. After fixation, a sample of the jejunum section of the small intestine was 
isolated, stained with osmium tetroxide, dehydrated, and embedded in resin. Ultrathin 
sections were stained with lead citrate and uranyl acetate and examined using a Tecnai 




3.3.11 Cytoplasmic lipid droplet size analysis 
Thirty cells were examined from (n=3 mice) from each treatment group. The cells 
analyzed were located in the middle section of the villi and at least 3 villi were measured 
per mouse. CLD diameter was measured using ImageJ. Image stitching was performed 
using Autostitch.. Data is expressed as mean ± SEM. Statistical significance was 
determined using a Type 3 mixed model for fixed effects using SAS v 9.4; P<0.05 was 
considered significant. Lipid droplet size distribution was analyzed by two-sample 
Kolmogorov–Smirnov test; P<0.05 was considered significant. 
 
3.4 Results 
3.4.1 Lipid accumulates in CLDs in enterocytes in response to an acute dietary fat 
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lean and DIO mice 
Neutral lipids accumulate in CLDs in enterocytes of the jejunum section of the 
small intestine in lean and DIO mice in response to an acute dietary fat challenge (Fig 1).  
The representative micrographs highlight the size disparity of CLDs that accumulate in 





3.4.2 CLDs in enterocyte of DIO mice are larger and have a different size distribution 
compared to lean mice in response to an acute dietary fat challenge 
The average CLD diameter was measured from 30 cells per mouse (n=3 mice) 
from each treatment group. No difference was observed in the number of CLD per cell in 
lean and obese mice in response to an acute dietary fat challenge (Figure 2a). DIO mice 
(black bars) have significantly greater CLD diameter compared to lean mice in response 
to an acute dietary fat challenge (Figure 2b). CLDs in enterocytes from DIO mice have a 
statistically significant size distribution compared to lean mice in response to an acute 
dietary fat challenge as determined by two-sample Kolmogorov–Smirnov test (Figure 2c). 
 
3.4.3 Proteins were identified associated with isolated CLDs from lean and DIO mice in 
response to an acute dietary fat challenge 
To identify proteins which may contribute to the size distribution disparity 
between the lean and DIO mice in response to an acute dietary fat challenge, we 
identified proteins associated with isolated CLDs by LC MS/MS. A protein was 
considered identified in a treatment group if it was identified in at least 3 out of 5 
biological replicates in at least one of the treatment groups. We identified a total of 375 
proteins (Data not shown). Of the 375 identified proteins, a portion was found unique to a 
treatment group, some found at similar levels and others were found at differentiated 





3.4.4 Proteins identified associated with CLDs from lean and DIO mice are associated 
with a variety of biological processes 
The gene ontologies associated with the 375 identified proteins were compared to 
the complete mouse proteome and visualized using GOrilla (Data not shown). GOrilla 
highlights biological processes which are enriched within the CLD associated protein 
dataset. Biological processes highlighted in red indicate the most significant enrichment. 
The proteins identified in the current analysis are associated with a wide variety of 
biological processes (Data not shown). Biological process pathways that have the greatest 
enrichment include oxidation-reduction process (GO:0055114), cellular lipid catabolic 
process (GO:0044242), and organonitrogen compound metabolic process (GO:1901564). 
To identify proteins which may contribute to CLD size and lipid accumulation, we 
limited our analysis to the 81 (out of 375) proteins that are associated with lipid related 
processes as determined using GOrilla (Data not shown). 
 
3.4.5 Proteins associated with lipid related processes are found at differentially present 
levels and have been previously characterized associated with CLD in enterocytes 
proteomic or targeted protein analysis 
Of the 81 lipid related proteins identified in the analysis, 25 are found either 
unique or at differentiated present levels in lean and DIO samples (Table 1)Targeted 
STRING analysis of lipid related proteins identify interacting protein clusters associated 




To identify lipid functional pathways enriched in the CLD proteome, we 
conducted a STRING analysis of the 81 lipid related proteins (Figure 4). The STRING 
analysis identified protein clusters related to lipoprotein metabolism, TAG storage and 
mobilization, and fatty acid catabolism.The 25 proteins which are found unique or at 
higher levels in either lean or DIO samples are indicated by green and red boxes 
respectively and their relative levels are found in Table 1. Proteins found at higher levels 
in DIO samples are associated mainly with fatty acid catabolism, lipid synthesis, and 
lipid catabolism. 
 
3.4.6 Plin3 and Plin2 localize to CLDs from lean and DIO mice in response to an acute 
dietary fat challenge. 
To confirm the presence of CLD associated proteins identified by CLD proteomic 
analysis, we used immunofluorescence microscopy of 2 proteins which were identified, 
Plin2 and Plin3 (Figure 5). Plin3 (A-B and E-F) is found at relatively equal abundance 
associated with CLDs from lean (A-B) and DIO (E-F) mice. Plin2 (C-D and G-H) is 
found at higher levels and forming a more distinct ring like structure around CLDs from 
DIO mice (G-H) compared to lean mice (C-D). These results validate that Plin2 and 3 
associate with CLDs in lean and DIO mice and Plin2 is present at differentiated levels. 
An interesting observation was made regarding to the localization of Plin2 and Plin3, 





3.4.7 Plin2 and Plin3 localize to different CLDs in different regions of the cell in DIO 
mice. 
Plin3 (A, C, and E) localizes to CLDs primarily in the apical region (above the 
nucleus) of the cell. Plin2 (B, D, and F) localizes to CLDs both in the apical and 
basolateral side of the cell. 
 
3.5 Discussion 
We investigated the effects of DIO on enterocyte CLD morphology and 
associated proteins in response to an acute dietary fat challenge. DIO mice have larger 
CLDs with a greater maximal size compared to lean (Figures 1 and 2). 375 proteins were 
identified on CLDs from lean and DIO mice in response to an acute dietary fat challenge 
(Data not shown). A portion of the proteins were found unique to one of the treatment 
groups, a portion found at similar levels between the treatment groups, and some found at 
differentially expressed levels (Figure 3). The identified proteins represent a diverse 
range of proteins functions (Data not shown). Eighty one of the identified proteins are 
associated with lipid related pathways (Figure 4). Of the 81 lipid related proteins, 25 
proteins are either unique to CLDs from DIO mice or found at differentially present 
levels in lean and DIO mice in response to an acute dietary fat challenge based on label 
free quantitation levels (Table 1). Plin3 is found associated with CLDs from lean and 




 mice compared to lean in response to an acute dietary fat challenge (Figure 5). Plin2 and 
Plin3 are found on different pools of CLDs in DIO mice in response to an acute dietary 
fat challenge (Figure 6). 
DIO alters CLD size which may contribute to the observed decreased TAG 
secretion rates in DIO compared to lean mice in response to an acute dietary fat challenge. 
High fat diet fed (non obese), ob/ob mice, and DIO mice have decreased TAG secretion 
rates after an olive oil bolus, when lipoprotein lipase has been inhibited with tyloxapol [9, 
10]. Interestingly, while there is a decrease in TAG secretion, analysis of intestinal 
mucosa by either biochemical analysis or Coherent Anti-Scatter Ramen Spectroscopy[10] 
demonstrated no difference in TAG content between lean and DIO in response to an 
acute dietary fat challenge. The current study demonstrates an increased CLD size in DIO 
and lean mice in response to an acute dietary fat challenge by transmission electron 
microscopy. The difference between the current study and previous analysis of intestinal 
mucosa is the use of transmission electron microscopy to identify the subcellular 
localization of TAG in CLDs as compared to the analysis of the total enterocyte TAG 
content. Biochemical and CARS analysis cannot distinguish between subcellular 
localization of TAG in secretory or storage pathways in enterocytes. We hypothesize that 
the decreased TAG secretion rate and increased TAG storage in CLDs in DIO mice 
compared to lean in response to an acute dietary fat challenge may be an adaptation of 
DIO mice to chronic consumption of a high fat diet. Adaptation of enterocytes to chronic 





DIO alters CLD associated proteins in response to an acute dietary fat challenge. 
Previous observations identified Plin3 localized to the CLD of lean mice in response to 
an acute dietary fat challenge while Plin2 localized to the CLD of DIO mice under 
chronic high fat feeding [13]. This study is the first report of CLD associated proteins in 
enterocytes in DIO mice in response to an acute dietary fat challenge. Surprisingly, we 
identified Plin2 on CLDs from lean mice in response to an acute dietary fat challenge. In 
our previous report, we did not identify Plin2 associated with CLDs in enterocytes of lean 
mice in response to an acute dietary fat challenge [13]. The previous results are consistent 
with a lipid maturation hypothesis where Plin2 is thought of associating with more 
mature CLDs and Plin3 associates with nascent CLDs [22]. While it is unclear why Plin2 
was identified on CLDs from lean mice in response to an acute dietary fat challenge, 
there are differences in the methodology in the current study compared to previous data 
generated in our laboratory. The current study uses a more sensitive proteomic technique 
to identify CLD associated proteins. Additionally, fresh frozen tissue used in the current 
study allows for imaging of a greater number of enterocytes compared to isolated 
enterocytes used in the previous report [13]. As seen in Figure 5, the Plin2 antibody 
generates a weaker signal around the CLDs in lean mice compared to DIO mice in 
response to a dietary fat challenge. It is possible that Plin2 was undetected in previous 
reports because it was present at levels that were below the level of detection.  
Lipid related proteins which were found identified either unique or at higher 
abundance associated with CLD from DIO mice compared to lean in response to an acute 
dietary fat challenge are similar to those found in models of hepatic steatosis induced by 




proteins we compared the findings of the current study to a previous report of liver CLD 
associated protein induced by high fat feeding [12]. The liver is an appropriate model 
system to compare the small intestine to in regards to lipid metabolism because they 
share several common features such as the ability to generate both CLDs and lipoproteins. 
Although both liver and intestine are capable of generating both triglyceride rich particles, 
the liver is often thought as a storage site for TAG while the small intestine is thought of 
as a through fare for TAG. A model of diet induced hepatic steatosis was used for 
comparison. Hepatic steatosis was induced by chronic high fat feeding (60 kcal% Bio-
Serv, F3282 for 9 weeks) [12]. Several lipid related proteins which were found identified 
either unique or at higher abundance associated with CLD from DIO mice compared to 
lean in response to an acute dietary fat challenge which have also been previously 
reported in the models of hepatic steatosis include ApoC2, Faah, Abcd3, and Acadvl [12]. 
It is unclear if these proteins are present due to the effect of obesity on a CLD 
accumulation in response to an acute dietary fat challenge or if they are residual proteins 
present on CLDs induced by high fat feeding from the previous meal of high fat diet. The 
concept of proteomic differences between “old” CLD which are residual from the chronic 
consumption of high fat diet and newly formed CLDs generated in response to a meal is 
an interesting one, but this study does not address this issue. 
Different CLD pools have different protein composition in response to an acute 
dietary fat challenge. An unexpected observation made in this study was that Plin2 and 
Plin3 localize to different CLD pools in enterocytes of DIO mice in response to an acute 
dietary fat challenge (Figure 6). There are several lines of evidence suggesting that there 




them. While it has not been previously observed in the intestine, the perilipin family 
members associate with CLDs at different times during CLD maturation in adipocytes 
[22]. Additionally, members of the Cell death-inducing DNA fragmentation factor- -like 
effector (CIDE) family of proteins localize to different CLD subpopulations in 
hepatocytes[23]. Lastly, TAG synthesis enzymes localize to different CLD sub 
populations [24]. In particular AGPAT3 and GPAT4 colocalize on a subpopulation of 
CLDs. More recently, it has been hypothesized that two groups of lipid droplets exist in 
the cell. These CLDs are described as initial lipid droplets and expanding lipid droplets 
which have their own distinct protein compositions[25]. The current study provides 
supporting evidence for the possibility of different CLD subpopulations which have 
distinct sub-proteomes and unique metabolism. This study highlights the power of 
tandem mass spectroscopy to identify novel CLD associated proteins and compare the 
CLD proteome under different conditions, however it cannot distinguish between 
subpopulations of CLDs. This limitations highlights the need for microscopy techniques 
to confirm the presence of proteins on or around CLDs and if it the protein localizes to 
distinct CLD sub population.  
Proteins that associate with CLDs in lean and DIO mice in response to an acute 
dietary fat challenge are associated with a wide range of lipid related pathways (Figure 4 
and Table 1). Proteins associated with lipid anabolic and catabolic pathways localize to 
CLDs. TAG synthesis enzymes localize to CLDs in Cos7 cells[24] including GPAT4, 
AGPAT3, ACSL1 and 3, and DGAT2. In the current study we identify Mogat2, Acsl5, 
and Dgat1 associated with CLDs from DIO mice (Table 1). Although we did not measure 




response to an acute dietary fat challenge indicates the potential for localized TAG 
synthesis. Enzymes that regulate CLD lipolysis have been well characterized in other cell 
types including hepatocytes [26] and adipocytes [27] but enzymes that conduct  lipolysis 
in the intestine are under investigated. Several proteins which have been identified as 
lipases in other cell types have also been identified in this analysis. Lipe (Hormone 
sensitive lipase) was identified in CLDs from lean and DIO mice in response to an acute 
dietary fat challenge. Members of the carboxylesterase family have been identified on 
CLDs from lean and DIO mice. Some Carboxylesterase family members have been 
characterized as lipases, however the isoform Ces1f, which was identified on the CLD 
from DIO mice has not been characterized [28](Table 1), Arylacetamide deacetylase 
(Aadac) was identified on CLDs from lean and DIO mice but at higher levels on CLDs 
from DIO mice and has been characterized as a lipase in the HuH7.5 cells[29]. 
Additionally, members of the short-chain dehydrogenase/reductase family associate with 
CLD and may regulate TAG storage. Members of the short-chain 
dehydrogenase/reductase family including Dhrs1, HSD17B11, and HSD17B13 have been 
identified on the CLD from lean and DIO mice. The role of these proteins on the CLD is 
currently unknown, but evidence suggests that at least 1 family member, HSD17B13 is 
associated with human subjects with NAFLD and over expression results in increased 
accumulation of CLDs in mice[30]. 
The results from this study help generate a hypothetical model to generate 
hypotheses for further investigation (Figure 7) to explain the effect of DIO on intestinal 
lipid metabolism. DIO alters CLD morphology and associated proteins in response to an 




both anabolic and catabolic pathways. Proteins found associated with the CLD may 
regulate the balance between storage of dietary TAG and the mobilization of TAG to be 
utilized for chylomicron synthesis. The identification of proteins associated with TAG 
lipolysis and lipid synthesis associated with CLDs from DIO mice may indicate that 
mobilized FFA are being utilized for lipid synthesis directly on the CLD instead of being 
utilized for chylomicron synthesis. This is consistent with the previously reported 
decrease in TAG secretion observed in DIO mice in response to an acute dietary fat 
challenge. The identified CLD associated proteins provide potential targets for further 
investigation into the role of these proteins in dietary fat absorption  
We demonstrated that DIO alters CLD morphology and associated proteins in 
response to an acute dietary fat challenge. CLDs from DIO mice are larger with a 
different size distribution compared to lean mice. CLDs from DIO mice have some 
proteins in common and some unique compared to lean mice. Proteins found at higher 
levels or unique to CLDs from DIO mice are associated with lipid catabolic and anabolic 
pathways. Proteins identified in this analysis help expand upon the model of the effect of 
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Table 3-1 Label free quantitation of proteins associated with lipid related Gene Ontology 
terms. 
375 identified proteins, 81 proteins are associated with lipid related Gene Ontology terms 
as identified by GOrilla (Data not shown). Of the 81 lipid related proteins, 25 were found 






















protein, liver Fabp1 23.72 25.10 0.029 [7] Lipid binding 
Q9DBZ6 
ATP-binding cassette 
sub-family D member 3 Abcd3   22.20     





























hydrolase 1 Faah   20.65     Fatty acid catabolism 
Q91WU0 Carboxylesterase 1f Ces1f   22.64     Triglyceride lipase 
Q99PG0 
Arylacetamide 




acyltransferase ABHD5 Abhd5   21.53   [5, 6] Lipid homeostasis 
Q9QZQ8 
Core histone macro-
H2A.1 H2afy   21.56     




1 Adh1   20.21   [7] Lipid metabolic process 
Q8C3C9 
Fatty aldehyde 


















Table 3-1 Continued 
G5E850 Cytochrome b5 Cyb5 25.41 24.44 0.039 [7] Sterol biosynthesis 
Q9EQ06 
Estradiol 17-beta-
dehydrogenase 11 Hsd17b11 23.46 25.38 0.027 [5, 6, 7] Steroid synthesis 
P49586 
Choline-phosphate 
cytidylyltransferase A Pcyt1a 22.63 21.52 0.021 [5] Phospholipid synthesis 
Q80W94 
2-acylglycerol O-
acyltransferase 2 Mogat2   19.78   [4] Triglyceride synthesis 
H7BXC3 
Triosephosphate 









[NAD(+)], cytoplasmic Gpd1   21.01   [7] G3P metabolic process 
Q8VCR2 
17-beta-hydroxysteroid 
dehydrogenase 13 Hsd17b13   21.88     
Oxidation-reduction 
process 
Q3UJG0 Apolipoprotein C-II Apoc2   19.12     Lipoprotein metabolism 
Q3U711 Perilipin-2 Plin2 23.92 25.99 0.026 
[4, 5, 6, 
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CHAPTER 4. LONG CHAIN FATTY ACYL COA SYNTHETASE 5 ABLATION 
DECREASES TRIGLYCERIDE STORAGE IN ENTEROCYTES AND 
SECRETION IN RESPONSE TO AN ACUTE DIETARY FAT CHALLENGE 
COMPARED TO WILD TYPE MICE 
4.1 Abstract 
Acyl-CoA synthetases (ACSs) activate fatty acids generating fatty acyl-CoA 
which is further metabolized by the cell. One member of the ACS family, long chain fatty 
acyl Co-A synthetase 5 (Acsl5), is highly expressed in the intestine. Little is known of the 
role of Acsl5 in the metabolism of dietary fat in enterocytes. To understand the role of 
Acsl5 in dietary fat absorption, we challenged WT and Acsl5-deficient mice with acute 
and chronic dietary fat challenges. Despite no evidence of quantitative fat malabsorption 
in the absence of Acls5, we found significantly reduced TAG storage and secretion by 
enterocytes compared to WT mice.  Interestingly, Acsl5-deficient consumed more food, 
but did not gain more weight compared to WT mice during two weeks of HFD feeding. 
Furthermore, we found that Acsl5 localizes to the nucleus after an acute dietary fat 
challenge. Together this data suggests that although Acsl5 is not essential for quantitative 





ACSs initiate the first step of fatty acid metabolism in the cell by converting fatty 
acid to fatty acyl-CoA [1].There are 25 known members of the ACS family with different 
tissue distribution patterns and fatty acid substrate preferences. Long chain fatty acyl 
CoA synthetases (Acsls) prefer long chain fatty acids with chain lengths of 13-21 carbons. 
Acsl5 is highly expressed in the small intestine, liver, and brown adipose tissue [2]. Acsl5 
has multiple subcellular localizations including mitochondria [3-6] and ER [2, 5]. More 
recently, Acsl5 was also identified [7, 8] and confirmed [8] to be associated with CLDs in 
enterocytes. Multiple areas of sub cellular localization of Acsl5 suggest Acsl5 may play 
multiple roles in cellular lipid metabolism.  
ACSs can have multiple functions in cells including fatty acid uptake and 
partitioning of fatty acids into different metabolic fates [9]. Over-expression of Acsl5 in 
McArdle-RH7777 cells, a rat hepatoma cell line, increased fatty acid uptake, and 
preferentially directed exogenous fatty acids toward TAG synthesis [3]. In a separate 
study, knocking down Acsl5 by siRNA in rat primary hepatocytes decreased fatty acid 
channeling toward anabolic pathways [10]. In this model, knocking down Acsl5 
decreased incorporation of fatty acids into TAG, phospholipids, and cholesterol esters, 
but did not affect fatty acid uptake. The decrease in incorporation of fatty acids into 
complex lipids was accompanied by decreased CLD formation and lipoprotein secretion. 
Lastly, Acsl5 knockdown cells have increased fatty acid oxidation. These results suggest 




To investigate the role of intestinal Acsl5 in dietary fat absorption, Meller et al. 
generated an Acsl5-deficient mouse model[11]. Acsl5-deficient mice had a 60% decrease 
in total ACS activity in the jejunum compared to WT mice. Despite the decrease in 
ACSL activity, Acsl5-deficient mice had similar TAG secretion in response to an acute 
dietary fat challenge compared to WT mice. Additionally, Acsl5-deficient mice had 
similar growth curves when fed a Western Diet (17% protein, 49% carbohydrates, 21% 
fat) compared to WT mice. This data suggests that Acsl5 does not play a role in dietary 
fat absorption by the small intestine. 
A new Acsl5-deficient mouse model has been generated with an improved 
metabolic phenotype compared to WT mice. Whole body deletion of Acsl5 resulted in a 
reduction of total Acsl activity by  80% in jejunal mucosa,  50% in liver, and  37% in 
brown adipose tissue lysates [12]. Overall Acsl5-deficient mice had decreased fat mass, 
increased metabolic rate, increased respiratory quotient, reduced serum TAG, and 
improved insulin sensitivity. This is the mouse model that was used for this study. 
To determine the role of Acsl5 in dietary fat absorption we challenged Acsl5=deficient 
and WT mice with acute and chronic dietary fat challenges. We hypothesized that Acsl5 
directs fatty acids toward TAG synthesis and that the absence of Acsl5 would result in a 
decrease in enterocyte TAG storage in CLDs and a decreased secretion rate in response to 
an acute dietary fat challenge. To test this hypothesis we analyzed TAG storage in the 
jejunum section of Acsl5-deficient mice compared to WT mice in response to an acute 
dietary fat challenge. Additionally, we measured TAG secretion in response to an acute 




deficiency results in fat malabsorption as indicated by steatorrhea, we fed Acsl5-deficient 
and WT mice a high fat diet and measured fecal lipid content. 
 
4.3 Materials and methods 
4.3.1 Diets and mice 
All procedures were approved by the Purdue Animal Care and Use Committee. A 
conditional, Acsl5-deficient mouse line was generated by Dr Andrew Greenberg at Tuft’s 
University and backcrossed to C57Bl6J line as previously reported (Bowman 2016).  All 
mice were maintained on a 12- hour light/dark cycle (6AM/6PM) with ad libitum access 
to food and water unless indicated. Mice were fed a chow diet or where indicated, a high 
fat diet. This chow diet (PicoLab 5043, Lab Diets, Richmond, IN) has 62.1% of calories 
from carbohydrate (starch), 24.7 % from protein, and13.2% from fat. The high fat diet 
(D12492, Research Diets Inc, New Brunswick, NJ) has 20% calories from carbohydrate 
(35% sucrose, 65% from starch), 20% from protein, and 60% from fat (lard). Mice were 
euthanized via CO2 asphyxiation. 
 
4.3.2 Tissue imaging 
Mice were fasted for 4 hours at the beginning of the light cycle. Mice were then 
 	   
  olive oil bolus via oral gavage. Mice were euthanized 2 hours after 
the oil bolus by CO2 asphyxiation. The small intestine was isolated and flushed with ice 




were analyzed. A small 1 cm2 section of the intestine was taken and cut longitudinally 
exposing the lumen. The section was embedded in optimal cutting temperature media 
(OCT) and frozen in 2-Methylbutane cooled by dry ice. Embedded tissue was stored at -
20  C until sectioned.  
    	 
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  	 
	 	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plus charged microscopy slides (Fisher scientific, Hanover Park, IL, USA). The tissue 
was fixed in 2% paraformaldehyde, and permeabilized with 0.1% saponin. The tissue was 
probed with a previously validated antibody Acsl5 (a gift from Dr. Andrew Greenberg 
from Tufts University, Boston MA, USA). The sections were also stained for neutral 
    -difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene 
(BODIPY) (Life technologies, Grand Island NY, USA), a secondary AlexaFluor antibody 
(Life technologies), and for nuclei using 300 nM DAPI (Life technologies). The sections 
were imaged using a Nikon A1R confocal microscope (Nikon Instruments Inc., Melville 
NY, USA). Image processing was conducted using NIS- Elements C acquisition and 
analysis software. 
4.3.3 TAG secretion 
To assess TAG secretion in response to an acute dietary fat challenge, mice were 
fasted for 4 h, starting at the beginning of the light cycle. Mice were then injected with 
tyloxapol (500 mg/kg) IP to block lipases required for clearance of TAG from blood. 
Thirty minutes after tyloxapol injection, blood was collected via submandibular bleed for 
analysis of plasma TAG concentrations (Time 0). Mice were then immediately gavaged 
      	  





gavage for plasma TAG analysis. Plasma TAG concentrations were determined by Wako 
L-Type TG M kit (Wako Chemicals USA). 
 
4.3.4 High fat feeding and food intake analysis 
Mice were fed a high fat diet (60% kcal) for 2 weeks and body weights 
determined weekly. To determine food intake, mice were housed individually in 
metabolic cages and food was weighed daily for the last 4 days of high fat feeding. 
 
4.3.5 Fecal lipid analysis 
To assess fecal lipid content, feces were collected from mice for the last 4 days of 
the 2 week high fat diet feeding. Feces were dried, weighed, ground using mortar and 
pestle, and 0.5g was used for lipid analysis. Lipids were extracted using the Folch 
extraction (2:1 chloroform: methanol) procedure. Percent fecal lipid content was 
determined: (mg extracted lipid/mg dried feces)*100. 
4.4 Results  
4.4.1 Acsl5-deficient mice accumulate less neutral lipids in CLDs in response to an 
acute dietary fat challenge compared to WT mice. 
To assess the effect of Acsl5 on enterocyte neutral lipid storage in response to an 
   	 
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isolated, sectioned and stained for Acsl5, neutral lipids, and nuclei (Figure 1). Acsl5 is 
present in enterocytes of WT mice (Fig 1A) but absent in Acsl5-deficient mice (Fig 1D). 
WT mice had greater accumulation of neutral lipids (orange) (Fig 1B) compared to 
Acsl5-deficient mice (E) in response to an acute dietary fat challenge. 
 
4.4.2 Decreased TAG secretion in Acsl5-deficient mice compared to WT mice. 
    	 
 	  	    	 olive oil bolus was 
administered to WT and Acsl5-deficient mice pretreated with a lipase inhibitor, that 
prevents clearance of TAG from blood, Tyloxapol. Blood was collected at T=0, 2, and 4 
hours after the olive oil bolus. TAG secretion at 4 hours after an acute dietary fat 
challenge was significantly reduced in Acsl5-deficient compared to WT mice (Fig 2). 
 
4.4.3 Acsl5-deficeint mice have increased food intake without differences in body 
weight or fecal lipid content compared to WT mice when fed a high fat diet. 
To assess the effect of Acsl5 deficiency on weight gain, food intake, and 
quantitative dietary fat absorption, WT and Acsl5-deficient mice were fed a HFD (60% 
kcal) for two weeks body weight, food intake, and fecal lipid content were determined.  
WT and Acsl5 had similar body weight curves during this time period (Fig 3a).  Despite 
similar body weight gain, Acsl5 deficient mice consumed significantly greater amounts 
of food compared to WT mice during the last 3 days of HFD feeding (Fig 3b) with 





4.4.4 Nuclear localization of Acsl5 in enterocytes in response to an acute dietary fat 
challenge in WT mice. 
To assess Acsl5 subcellular location in enterocytes in response to an acute dietary 
  	
     l bolus was administered to WT mice by oral gavage. 
Samples from the jejunum section of the small intestine were isolated before the oil bolus 
(after a 4 hour fast) and two hours after the oil bolus. The small intestine was isolated, 
sectioned, and probed for Acsl5 (green) and counter stained for lipid (Bodipy, orange) 
and nuclei (DAPI, blue) (Figure 4). Before the oil bolus, Acsl5 is found dispersed in the 




To understand the role of Acsl5 in dietary fat absorption, we challenged WT and 
Acsl5-deficient mice with acute and chronic dietary fat challenges. Despite no evidence 
of quantitative fat malabsorption in the absence of Acls5, we found significantly reduced 
TAG storage and secretion by enterocytes compared to WT mice.  Interestingly, Acsl5-
deficient consumed more food, but did not gain more weight compared to WT mice 
during two weeks of HFD feeding. Furthermore, we found that Acsl5 localizes to the 
nucleus after an acute dietary fat challenge. Together this data suggests that although 
Acsl5 is not essential for quantitative dietary fat absorption, it plays a role in intestinal 




 Members of the ACSL family have been identified associated with CLDs and 
contribute to CLD metabolism [13]. Recent proteomic analyses of isolated CLDs from 
enterocytes identified [7, 8] and confirmed [8] Acsl5 localization to CLDs after a lipid 
challenge. We found less TAG storage in CLDs in Acsl5-deficient mice in response to an 
acute dietary fat challenge compared to WT mice. These results are similar to those 
observed in primary rat hepatocytes where Acsl5 knockdown resulted in a decrease in 
TAG storage [10]. Taken together, these results suggest that Acsl5 works in concert with 
TAG synthesis machinery on the CLD to generate TAG for storage.  
  Blood TAG levels in the postprandial state are a balance between TAG secretion 
from the intestine and clearance by peripheral tissues. We found that Acsl5-deficient 
mice have reduced TAG secretion in response to an acute dietary fat challenge compared 
to WT mice. These results are in contrast to previous reports from a different mouse 
model that is also deficient in Acsl5 where TAG secretion rates were found to be similar 
to WT mice [11]. There are several important differences between the two studies. The 
differing genetic backgrounds might explain some of the observed phenotypic differences. 
The Bowman Acsl5-deficient mice were on a pure C57BL6J background while the 
Meller Acsl5-deficient mice were on a mixed C57BL6J/129sJ background. The Bowman 
Acsl5-deficient mice had reduced total ACSL activity in liver extracts consistent with 
previous published studies showing that siRNA knockdown of ACSL5 in isolated 
hepatocytes significantly reduced total ACSL activity [10]. Meller et al. did not report the 
expression of all of the other ACSL isoforms in their mouse livers, thus, another ACSL 
isoform may have compensated for any reductions in ACSL activity. The two studies also 




the amount of dietary fat which was used to challenge the mice. The Meller mouse model 
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stress the intestine to delineate differences between Acsl5 deficient and WT mice. The 
second issue regarding the TAG secretion assay is the time period of assessment. The 
Meller mouse model collected blood samples until 90 minutes. In the current study, we 
collected samples 4 hours after the dietary fat challenge and it was only at the 4 hour time 
point that TAG secretion differs between Acsl5 deficient and WT mice. These data 
suggests that Acsl5 regulates dietary fat secretion in the small intestine, however under 
specific physiological conditions.  
Deficiencies in dietary fat uptake and secretion are often accompanied by fat 
malabsorption. Since Acsl5 deficient mice have a decrease in TAG storage and TAG 
secretion compared to WT mice, we analyzed fecal lipid content in mice fed a high fat 
diet to assess steatorrhea. Surprisingly, Acsl5 deficient mice do not have an increase in 
fecal lipid content compared to WT mice when fed a high fat diet. One hypothesis to 
explain this observation is Acsl5 deficient mice take up fatty acids in different regions of 
the small intestine compared to WT mice. Acsl5 deficient mice may have lower rates of 
fatty acid uptake in enterocytes in the upper region of the intestine; instead take up 
dietary fatty acids in smaller quantities in different regions. By diffusing dietary fat 
uptake along the length of the intestine, Acsl5 deficient mice can have decreased TAG 
secretion rates and TAG storage without fat malabsorption. In this study we only assessed 




secretion and uptake on a whole body physiological level.  Future studies to assess fatty 
acid uptake and TAG storage and secretion at a cellular level in specific regions of the 
small intestine are important to clarify this issue.  
We also investigated weight gain and food intake of high fat diet in Acsl5 
deficient mice and WT mice. Acsl5-deficient and WT mice consumed similar quantities 
of food when fed a chow diet [12]. When Acsl5-deficient mice were fed a HFD however, 
Acsl5-deficient mice consumed significantly more food compared to WT mice. Increased 
food intake may be attributed to a number of factors and the factors which influence an 
increase in food intake on a HFD in Acsl5 deficient compared to WT mice have not been 
studied. One hypothesis for increased food intake in Acsl5 deficient mice compared to 
WT mice is an increased circulating level of FGF21[12]. Overexpression of FGF21 
increases food intake when mice are fed chow or high fat diets [15]. Acsl5-deficient mice 
may consume more high fat diet compared to WT mice due to their increased levels of 
serum FGF21. Despite the increase in food intake, Acsl5 deficient mice had similar 
weight gain on high fat diet compared to WT mice when fed for a 2 week period. The 
increase in caloric intake may be offset by the increased energy expenditure in Acsl5-
deficient mice compared to WT mice [12].  
A surprising observation made during imaging of Acsl5 in response to an acute 
dietary fat challenge was the dramatic change in subcellular localization of Acsl5. In the 
before an oil bolus, Acsl5 is found dispersed in the cell, however when WT mice are 
given an acute dietary fat challenge, Acsl5 distinctly localizes to the nucleus of 
enterocytes. Acsl5 is known to localize to mitochondria and CLDs in enterocytes [4, 8]  




enterocytes. The presence of long chain fatty acyl-CoA and ACSLs has been detected in 
the nucleus of rat liver [16-20]. Acyl-CoAs are thought to be present within the nucleus 
and serve as ligands for transcription factors that may regulate expression of proteins 
involved in TAG storage and secretion. Acyl-CoAs may be transported into the nucleus 
or based on this observation generated within the nucleus. This unexpected discovery 
represents a very interesting area for future research. 
Acsl5 plays a role in intestinal lipid metabolism in response to dietary fat. Despite 
no evidence of quantitative fat malabsorption in the absence of Acls5, we found 
significantly reduced TAG storage and secretion by enterocytes compared to WT mice.  
Interestingly, Acsl5-deficient consumed more food, but did not gain more weight 
compared to WT mice during two weeks of HFD feeding. Furthermore, we found that 
Acsl5 localizes to the nucleus after an acute dietary fat challenge. Together this data 
suggests that although Acsl5 is not essential for quantitative dietary fat absorption, it 
plays a role in intestinal metabolism of dietary fat. 
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Figure 4-2 Decreased TAG secretion in Acsl5-deficient mice compared to WT mice. 
 
Postprandial TAG secretion rate was measured in WT and Acsl5 -/- mice. Mice were 
injected with 500 mg/kg Tyloxapol into the interperitoneal cavity to inhibit lipoprotein 
lipase activity. Thirty minutes after Tyloxapol injection, the mice were bled (T=0) and 
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post oil bolus. Data represented as mean +/- SEM. Asterisk denotes significant difference 























































Figure 4-3 Acsl5-deficeint mice have increased food intake without differences in body 
weight or fecal lipid content compared to WT mice when fed a high fat diet 
No different in body weight between Acsl5-/- and WT mice on a high fat diet for 2 weeks. 
Body weights of Acsl5 -/- and WT mice fed a high fat diet (60% kcal) were monitored 
for 2 weeks (A). No difference in body weight was determined using a Student t test 
(p<.05) Data represented as mean +/- SEM. n= 4-5 mice. Increased food intake of Acsl5 -
/- mice compared to WT mice when fed a high fat diet (B).Food intake was monitored 
during the last 4 days of a two week period of high fat diet (60% kcal) feeding. Acsl5 -/- 
mice had increased food intake compared to WT mice as determined by a Student t test (* 
p<.05). Data represented as mean +/- SEM n= 4-5 mice. No difference in fecal lipid 
content in Acsl5 -/- compared to WT mice after 2 weeks of high fat feeding (C). Acsl5 -/- 
and WT mice were fed a high fat diet (60% kcal) for 2 weeks. Fecal samples were 
collected during the last 4 days of feeding. Lipid content was determined by Foch 
extraction of ground feces. Data represented as mean +/- SEM. No difference in fecal 
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CHAPTER 5. SUMMARY AND FUTURE DIRECTIONS 
5.1 Summary 
Dietary fat provides essential nutrients, contributes to energy balance, and 
regulates blood lipid concentrations. These functions are important to health, but can also 
become dysregulated and contribute to diseases such as obesity, diabetes, cardiovascular 
disease, and cancer. Within enterocytes, the digestive products of dietary fat are re-
synthesized into triacylglycerol, which is either secreted on chylomicrons or stored within 
cytoplasmic lipid droplets (CLDs). CLDs were originally thought to be inert stores of 
neutral lipids, but are now recognized as dynamic organelles that function in multiple 
cellular processes in addition to lipid metabolism. The objective of this dissertation was 
to investigate CLDs and associated proteins and their role in dietary fat absorption.  
To identify regulators of CLD metabolism we analyzed the proteomic profile of 
isolated CLDs from enterocytes in response to an acute dietary fat challenge. We 
identified 181 proteins associated with the isolated CLD fraction using high resolution 
tandem mass spectrometry. Interestingly, the identified proteins are associated with a 
wide range of biological and molecular functions. Several of the identified proteins have 
been previously identified in other CLDs proteomic analyses from many cell types, while 
other identified proteins have not been previously reported. Furthermore, we confirmed 




immunoelectron microscopy. Additionally, we investigated the effect of DIO on 
intestinal CLD morphology and associated proteins. We demonstrated that DIO mice 
have larger CLDs compared to lean mice in response to an acute dietary fat challenge. 
CLDs isolated from DIO mice have some proteins in common and some unique 
compared to CLDs isolated from lean mice in response to an acute dietary fat challenge. 
Proteins found at higher levels or unique to CLDs isolated from DIO mice are associated 
with both lipid anabolic and catabolic pathways. The newly identified CLD associated 
proteins expand upon the model of protein regulators of CLD metabolism in enterocytes.  
Lastly, we investigated the role of Acsl5 in dietary fat absorption. To characterize 
the role of Acsl5 in the small intestine we challenged Acsl5-deficient mice and WT mice 
with acute and chronic dietary fat challenges. We demonstrate Acsl5-deficient mice have 
decreased TAG secretion and decreased neutral lipid storage in response to an acute 
dietary fat challenge. Additionally, we show Acsl5-deficeint mice have no defect in 
quantitative dietary fat absorption when placed on a high fat diet for two weeks. 
Additionally, Acsl5-deficient mice have increased food intake without associated weight 
gain compared to WT mice when fed a high fat diet. Lastly, we observed a dramatic shift 
to nuclear localization of Acsl5 in response to an acute dietary fat challenge. Taken 
together, these results indicate that Acsl5 plays an important role in dietary fat 
metabolism.  
The results presented in this dissertation identify new regulators of CLD 
metabolism and dietary fat absorption in the small intestine. These results provide the 





5.2 Future directions 
The chapters in this dissertation highlight how much is unknown regarding the 
role of CLDs in dietary fat absorption. Several areas of unanswered questions include 1) 
identifying differences in CLD morphology and associated proteins in different regions 
of the intestine, 2) identifying changes in CLD morphology and associated proteins over 
time, and 3) what role Acsl5 plays in the nucleus of enterocytes. 
 
5.2.1 CLD morphology and associated proteins along the length of small intestine 
Enterocytes along the length of the intestine are capable of absorbing dietary fat 
however the mechanistic details of dietary fat absorption along the length of the intestine 
is relatively unknown. When a small amount of dietary fat is administered, the majority is 
taken up in the proximal section of the intestine. When dietary fat load increases, the 
lower region of the small intestine absorbs dietary fat [1]. Most dietary TAG is taken up 
and stored in CLDs in the proximal section of the small intestine, however TAG storage 
occurs along the length of the intestine with smaller quantities found in the distal regions 
[2]. Little is known about CLD morphology and associated proteins in the duodenum and 
ileum. Regulators of CLD metabolism may differ in different regions of the intestine and 
alter that region’s contribution to post prandial lipedema. Identifying CLD associated 
proteins along the length of the intestine is important for identifying regulators of dietary 




5.2.2 Changes in CLD morphology and associated proteins over time in response to an 
acute dietary fat challenge. 
CLDs are dynamic stores of TAG which increase and decrease over time in 
response to an acute dietary fat challenge [2]. This dynamic nature is most likely 
regulated by proteins which associate with the CLD. CLD protein composition changes 
over time in other cell types [3, 4]. We hypothesize CLDs associated proteins in 
enterocytes change over time as CLDs grow and shrink. To test this hypothesis, we 
would administer an acute dietary fat challenge to mice and isolate CLDs from 
enterocytes at 1, 2, 4, and 6 hours after the bolus. Proteins associated with the CLDs at 
these time points will be identified by high resolution tandem mass spectroscopy.  
We would predict protein composition to change based on protein function and 
protein structure. We would predict proteins identified at earlier time points would 
include more lipid synthesis proteins compared to later time points. Lipid synthesis 
enzymes would allow nascent CLDs to grow and store TAG and other neutral lipid 
species. Conversely we would expect more lipid catabolism proteins to be present on 
CLDs at later time points compared to earlier time points to mobilize stored lipid.  
Additionally, we would predict protein composition to change over time based on 
protein structure. Proteins identified at later time points may have structural features 
which would allow the protein to directly bind to CLDs. Proteins loosely associated with 
CLDs are predicted to be displaced as stored TAG is catabolized and the CLDs shrink [5]. 
Identifying how CLD associated proteins change over time can identify important 




5.2.3 The role of Acsl5 in the nucleus 
Localization of Acsl5 to the nucleus of enterocytes in response to dietary fat 
challenge may regulate dietary fat absorption in the small intestine. Long chain fatty acyl-
CoA has been identified in the nucleus in other cell types. Isolated nuclei from rat livers 
contain C16:1-CoA and C18:3-CoA [6, 7]. Additionally, long chain fatty acyl-CoA 
synthestase activity has been detected in isolated rat liver nuclei for a variety of long 
chain fatty acids [8, 9]. Lastly, long chain fatty acyl-CoAs act as ligands for hepatic 
nuclear factor 4 alpha (Hnf4a) [10].  
Hnf4a is expressed in the enterocyte and are activated by fatty acids derived from 
the luminal side of the enterocytes [11]. Hnf4a controls the expression of lipid 
metabolism genes including genes coding for apolipoproteins and microsomal 
triglyceride transfer protein (Mttp). Mice with an intestine specific inducible Hnf4a 
knockout have decreased triglyceride tolerance and decreased triglyceride secretion 
compared to Hnf4a loxp/loxp counterpart [12]. Hnf4a knockout mice have decreased 
Apolipoprotein B and Mttp protein expression, Mttp activity and decreased TAG 
accumulation in enterocytes in the post oil bolus state [13]. The similarities between 
Hnf4a knockout mice and Acsl5-deficient mice suggest the two proteins may share 
similar biological pathways or are mechanistically connected.  
We hypothesize that Acsl5 localizes to the nucleus in response to a dietary fat 
absorption to provide long chain fatty acyl-CoA to serve as ligands for Hnf4a. The 
nuclear localization of Acsl5 indirectly regulates intestinal dietary fat uptake, metabolism, 




Acsl5 in isolated nuclei from enterocytes. We will confirm the presence of Acsl5 in 
isolated nuclei by Western Blotting analysis and acyl-coa synthetase activity using a 
variety of long chain fatty acids in an activity assay. Additionally, we will look at 
expression of Acsl5 downstream target genes in the post bolus state in WT and Acsl5-
deficeint mice. Finally, we will determine the binding of Hnf4a to downstream targets 
using an electrophoretic mobility shift assay in WT and Acsl5-deficient mice. The results 
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